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SECTION I
 
A. CONTRACT SUMMARY
 
I. 	 INTRODUCTION 
I A. CONTRACT SUMMARY 
The Study of Applications of Bio-Space Technology to Patient Monitoring Systems was con­
ducted for NASA by the Re-entry and Environmental Systems Division of the General Elec­
tric Company under Contract NASW-2073 during the last half of 1970. The primary pro­
gram objective was to establish the potential for application of NASA developed technology 
to cardiovascular and pulmonary patient monitoring to achieve improved availability, 
reliability and utility of data for medical use. Salient activities included: 
* 	 Survey and evaluation of existing patient monitoring systems within selected 
medical centers 
* 	 Preparation of a preliminary system requirements specification for a cardio­
pulmonary patient monitoring system 
* 	 Definition and rationale for a preliminary preferred system configuration ­
including estimated cost and schedule for prototype development 
* 	 Identification of critical areas of patient monitory techniques requiring further 
research and development - including estimated cost and schedule 
The groundwork for these detail tasks, including survey of medical centers, hardware ven­
dors and medical professionals, has been documented in periodic progress reports issued 
18 August 1970 and 8/9 October 1970. The second report was supplemented by a volume 
titled "Summary of Biosatellite Technologies", providing a comprehensive guide to poten­
tial medical applications of Bioscience/Aerospace experience, capabilities and hardware 
developments. A third progress report dated 8/9 December 1970 presents initial data 
for those tasks noted above, namely: 
* 	 The preliminary patient monitoring system specification 
* 	 The configuration trade-off study and selection of preliminary configuration with 
tentative implementation schedule 
* 	 The definition of .15technical areas for further research and development with 
tentative milestone schedules 
A Summary of the Program Effort 
A detailed report of the program effort is presented in the basic volume of the final report. 
This Final Report Supplement delineates the Preliminary Program Plan, Management Plan, 
and the budgetary cost and schedule data associated with the implementation of a patient 
monitoring system prototype and performance of recommended R&D tasks. 
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I B. 	 RECOMMENDED PATIENT MONITORING SYSTEM DEVELOPMENT 
The Patient Monitoring System recommended as a result of this study has the following 
characteristics: 
(1) 	 Modular concept allowing for scheduled growth, selection of options,and
 
improved maintainability.
 
(2) 	 Four basic physiologic monitoring modules: 
I 	 Cardiac 
I Cardiovascular 
II Pulmonary 
IV 	 Body Chemistry 
(3) 	 Each modular configuration!iIncludes computional capability which is provided by 
a mini computer. 
(4) 	 Module II'- Cardiovascular must interface via its local processor with a
 
full scale computer either on site or remotely accessed; remaining
 
modules may interface with a larger computer for achieving extended 
capabilities. 
(5) 	 A modular Nurses Station capable of growth by add-on; basic station handles 
four patients. 
(6) 	 Displays at bedside and/or nurses station include patient vital signs, ECG 
trace (with recording on alarm), physiologic alarm, equipment alarm, and any 
stored, entered or monitored data selected for display via alpha-numeric­
graphic (A/N/G) CRT with keyboard. 
(7) 	 Remote monitors consisting of A/N/G CRT and keyboard. 
(8) 	 Peripheral equipment for program loading, debugging, system maintenance, etc. 
Development of a prototype patient monitoring system for clinical demonstration is 
recommended. Preliminary work statement, schedules, potential demonstration configura­
tions and budgetary cost estimates are delineated in Section H B. 
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It is recommended that the patient monitoring system concept resulting from this study, 
which is in the form of a preliminary system specification, be further developed through 
a design specification and then implemented as a prototype for clinical evaluation. 
The interest expressed by the Steering Committee at the 3rd Progress Report Meeting 
along with subsequent evaluation by the study team indicates that either Module U (Cardio­
vascular) or Module HI (Pulmonary) would be logical candidates for further development 
and clinical evaluation. 
Module I, Cardiac Surveillance, was not considered by the study team on the basis of its 
cost and present lack of computer programs for the detection and classification of arrhythmia. 
This basic cardiac surveillance capability can be achieved by incorporating this in the Cardio­
vascular Module U. Module I was intended as an initial and basic step that a hospital could 
take in evolving a computerized patient monitoring capability: rirst by the addition of a 
minicomputer to interface with its existing cardiac monitoring equipment, and then ex­
panding into the pulmonary and/or cardiovascular capabilities. 
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I C. RECOMMENDED RESEARCH AND DEVELOPMENT TASKS 
Seventeen technical tasks associated with patient monitoring which may benefit from applica­
tion of Bio-Space skills, approaches and developments were identified during contract per­
formance. Several tasks, as will be shown later, have a direct relationship to achievement 
of an optimized patient monitoring system. 
A detail description and proposed time duration for each task is given in Section II A - 5.0; 
Budgetary Cost Estimates are provided in Section II B - 6.0. 
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1. 0 SCOPE 
The Program Plan delineates the major task elements, subtasks, documentation and sche­
dule leading to implementation of a prototype Patient Monitoring System for clinical demon­
stration and evaluation. 
Similarly, detailed descriptions and performance time sheets are provided for each of 
seventeen recommended R&D tasks, including two tasks added since Progress Report Num­
ber Three (Tasks 1 and 2). 
This Program Plan is preliminary. Upon contractral agreement to perform one or more 
of the tasks delineated herein, a detailed Program Plan and associated documents, struc­
tired on the plan delineated in the following pages, will be prepared. 
11-3 
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2.0 OBJECTIVES
 
Primary objectives of the Program Plan include:
 
1. 	 Describe the approach to be taken in the overall implementation of the system, 
and the integration of appropriate R&D tasks. 
2. 	 Identify all program tasks required to implement the specified patient monitor­
ing system. 
3. 	 Delineate the recommended R&D tasks which will include stated objective, 
requirements, subtasks, and intended results. 
4. 	 Provide scheduling estimates required to support both the system implementation 
and performance of the tasks. 
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3,0 APPROACH 
Design of PIVIS 
The work performed on the study contract has resulted in the evolution of a conceptual de­
sign for a patient monitoring system. The concept utilizes a modular approach, and 
marries advanced state-of-the-art medical techniques to available low-cost, high-perfor­
mance minicomputers. The result is a system which will have wide applicability to a 
variety of hospitals by fulfilling a multiplicity of needs with the same basic equipment. 
It is recommended that the conceptual design be further developed and refined to evolve a 
system configuration which is oriented towards specific hardware and software. This 
detailed design work is further delineated by the tasks noted in the Section titled "System 
Implementation". 
Research and Development Tasks 
The research and development tasks defined herein address technologic activities in which 
GE-RESD has developed expertise from similar tasks encountered in Aerospace and 
related programs. Application of this capability to the tasks defined will provide a cost 
effective means of providing a coordinated resolution of those salient problems identified. 
A number of the tasks directly relate to optimization of elements of the Patient Monitoring 
System delineated above. These items are shown in a preliminary recommended sequence 
in the integrated performance schedule, Section II B - 6.0. Detail work elements for each 
recommended R&D task are also documented in paragraph 5.0 of this section. Technical 
tasks teams of personnel specifically oriented towards the technology involved will be 
assigned to those tasks selected for further effort. 
it is recommended that the integrated schedule be reviewed by appropriate medical pro­
fessionals and a task priority list be established for future effort. 
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4.0 PATIENT MONITOR SYSTEM IMPLEMENTATION 
The Preliminary Patien Monitoring System (PMS) defined in the progress reports in concep­
tual only. Initial steps leading to the potential implementation of PMS hardware and soft­
ware must therefore include the basic design tasks noted below. 
Task Descriptions 
1. 	 Review conceptual design and iterate requirements. Factor in results of consul­
tations with the study contract advisory board, and the reactions of hospitals who 
would be potential users of the system. Finalize measurement parameters and 
modular breakdowns. Issue the preliminary system requirements specification. 
2. 	 Perform detailed trade-offs in significant areas, including computation, data 
transmission, display techniques, sampling rates, blood and urine analysis 
techniques. Select approaches for system implementation considering overall 
cost, efficiency, patient usage, medical acceptance. 
3. 	 Select hardware approaches and software programs and algorithms to implement 
the functions required. Factor in the results of current or planned R&D activi­
ties to ensure the current and future timeliness of the system, including growth 
potential. 
4. Perform breadboard and computer simulation tests as necessary to validate the 
selection of hardware and software techniques. Iterate the design based on the 
results of these tests. 
5° 	 Generate system documentation including the final system requirements specifica­
tion, equipment specifications, software specifications, interconnection diagrams, 
block diagrams, timing and logic diagrams where appropriate, manufacturing and 
test plans. 
6. 	 Generate a firm estimate of costs to build, install and test the system based on 
quotations from vendors and internal estimates. 
7. 	 After review and integration with the customer, including incorporation of design 
review changes, initiate procurement activity. This task includes order of long 
lead items, supplier evaluations, bidder review and purchase order release. 
8. 	 Initiate the manufacturing cycle for prototype hardware. Fabricate and assemble 
detail parts and subsystems. 
9. 	 Where practical, initiate the test and validation cycle in parallel with manufac­
turing activity. Terminate the in-house test effort upon completion of successful 
demonstration of the supplied hardware as a system. 
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10. Initiate a clinical demonstration of the PMS in the assigned medical center. The 
supplied system will be validated followed by integration and validation of inter­
faces with equipment supplied by the medical center. An on-line clinical evalua­
tion of the PMS system will be accomplished for approximately four months. 
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4.1 PROPOSED SCHEDULE 
A proposed schedule (elapsed time) for implementation of the prototype Patient Monitoring
System is given in Figure IA-i. The implementation of a prototype system has three 
phases, all dependent upon initial customer authorization to proceed and the generation of 
firm cost estimates (see Figure IIA-2). The first phase following initial go-ahead involves 
generation of firm costs for Tasks 1-6 (design, evaluation and hardware costing). The 
second phase is accomplishment of Tasks 1-6 including design, breadboard evaluation,
documentation and generation costs for producing, testing and demonstrating a prototype 
Patient Monitor System. Based upon Phase I and II results, Phase HI is the manufacture 
of the prototype system, in-house test/validation, followed by the clinical demonstration. 
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4.2 REQUIREMENTS 
It will be necessary to determine the detail requirements of the specific application for 
which the system will be implemented. The assessment of the specific requirements will 
be coupled with the preliminary systems specification and will ultimately result in the 
generation of a design specification which will be the basis for design and procurement 
efforts. 
The 	requirements task of Phase 11 will consist of the following: 
1. Perform detailed systems requirements analysis of specific user' s requirements 
which result in an applicable system requirements specification factoring in: 
a. 	 immediate needs and specific application (CCU, ICU, O/R, etc.) 
b. 	 growth requirements 
c. 	 use of existing equipment/software 
d. 	 facility requirements 
e. 	 special design requirements (hardware and software) 
f. 	 personnel requirements 
2. 	 Perform trade-off evaluations relative to user's specific recuirements and hard­
ware/software requirements and capabilities. 
3. 	 Generate system documentation including a system design specification. 
4.3 DESIGN 
Specifications 
The formal source for the system engineering direction for the design effort will be the 
Design Specification. 
Design Tasks 
Systems Engineering shall maintain control of the technical integration of design efforts to 
assure the timely completion of design tasks and technical design compatibility. The 
basic tasks in the design area are as follows: 
1. 	 Perform system design 
2. 	 Design of subsystems 
* 	 sensors 
* 	 signal conditioning 
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* 	 data processing 
* . display 
* 	 control 
* 	 software 
* 	 data transmission 
* 	 special support subsystems, e.g., urine collection 
3. 	 Generate subsystem and system interface specifications as required 
4. 	 Conduct preliminary and final design reviews 
5. 	 Generate drawings and procurement documentation 
6. 	 Generate a Facility Specification if required 
4.4 MANUFACTUBING 
The manufacturing effort will consist of fabrication of the selected "make" items and sub­
sequent assembly of the make and buy items. The major manufacturing tasks are out­
lined as follows: 
1. 	 Establish a Make or Buy.list which will include potential vendors 
2. 	 Generate a Build Plan which encompasses both procured and make items and will 
include a fabrication and assembly flow chart 
3. 	 Generate the necessary material request forms (purchase orders) 
4. 	 Implement production and control plan 
4.5 QUALITY ASSURANCE 
Quality Assurance will be applied on a limited basis for the prototype development, and 
shall follow good commercial practice. Specific tasks include implementation of quality 
assurance provisions for: 
o vendor qualification and selection
 
" incoming inspection of purchased material
 
* in-process inspection of manufactured material
 
" final inspection prior to shipment for clinical evaluation
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4.6 INTEGRATED TEST PLAN 
The Integrated Test Plan will be a composite delineation of all tests to be performed during 
the implementation of the prototype patient monitoring system. It will provide a systematic 
approach to the various levels of testing required to verify the design and fabrication/ 
assembly of the system and subsystems. This approach is intended to provide the minimum 
number of tests in the most effective manner to assure validation of design integrity with 
respect to functional performance, safety and reliability. The plan will have a direct 
applicability to future developments. 
This plan also required each major vendor, e. g., computer subsystem, to submit for 
approval a test plan for the subsystem being supplied. The Integrated Test Plan will in­
clude the following: 
1. test schedules 
2. test flow plans 
3. development test descriptions 
4. component/subsystem test descriptions 
5. vendor test descriptions 
6. system validation test description 
4.7 OPERATIONS PLAN 
The Operations Plan will contain detailed task descriptions and schedules concerning the 
following operational aspects: 
1. installation 
* facility preparation 
* installation 
* verification 
* schedule 
2. training of user personnel 
* implementation of training plan 
* schedule 
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3. maintenance plan 
* general preventative maintenance 
* malfunction maintenance and repair 
0 spares provisioning 
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5.0 R&D TASK DESCRIPTIONS AND SCHEDULES 
During the course of contract performance, certain areas became apparent that could be en­
hanced by the systematic application of scientific, engineering, and operational research 
and development skills. 
The development of the recommendations for supplemental task effort occurred in three 
phases. The first phase involved the categorical listing and brief over-view of each of the 
Biosatellite products and technologies. Against each category was recorded a "shopping 
list" of possible applications of the Biosatellite products and technologies to the medical 
field-more specifically that of patient monitoring. In defining these potential applications, 
informal discussions related to several potential task categories were held with members of 
the advisory committee. A formal presentation and discussion of the completely developed 
list was then conducted at the second progress report session in Philadelphia. The next 
phase involved the incorporation of the advisory committee's recommendations which re­
sulted in a modified task list. Additional refinement of the list was made by eliminating 
those areas which did not have uniqu attributes and/or were not already commercially 
available. For each item of the modified list, a detailed explanation was developed along 
with estimates of schedule requirements (elapsed time). The majority of these R&D tasks 
were included for review by the advisory committee in the third progress report. 
After the Third Progress report was published and reviewed the third phase of development 
of the R&D tasks was begun. The tasks were changed as recommended by the advisory 
committee. Estimated schedules and costs were developed for the tasks as defined. 
Seventeen areas are identified for the application of bio-science, Bio-satellite, and/or aero­
space technologies to patient monitoring. These are summarized as follows: 
Biosatellite and Other Aerospace Technology 	 Application 
5.1 	 Complex systems integration; detailed Combined PM Systems. 
computer planning, programming and
 
operations
 
5.2 	 Extensive systems designs, measure- Evaluation of significant parameters of ex­
ment requirements definition; hi isting medical equipment. 
reliability parts program. 
5.3 	 Telemetry of physiological para- Patient monitoring using telemetry tech­
meters. niques. 
5.4 	 Aerospace experience in computer Computer analysis techniques for ECG 
analysis 	of complex waveforms, wave shape analysis, arrhythmia detection 
and classification, etc. 
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Biosatellite and Other Aerospace Technology 	 Application 
5.5 	 Same as 5 - Plus GMA (provisioning 
of Habitable Atmosphere). 
5.6 	 Same as 9 
5.7 	 Same as 8 plus extensive develop-
ment and test techniques, 
5.8 	 Aerospace experience in techniques 
for non-destructive testing. 
5.9 	 Systems engineering. High reliability 
parts, parts and materials standards. 
5.10 	 Primate heparin system technology 
in Biosatellite, pneumatic and fluid 
systems. 
5.11 	 Production of systems requirements 
in Biosatellite. 
5.12 	 Systems engineering in aerospace 
data handling and measurement 
systems, 
5.13 	 Biosatellite urine-analyzer. 
5.14 	 Phenol analysis of Biosatellite water 
supply, 
5.15 	 Day/night photographic surveillance 
of primates. 
5.16 	 Primate feces collection and storage 
unit with gas management assembly. 
5.17 	 Biosatellite urine transport system. 
Respiratory analysis that does not interfere 
with the patient. 
Amplifier and signal conditioner standard 
requirements specification. 
Narrow band video systems for remote 
patient monitoring, consulation and diag­
nosis. 
Non-Invasive techniques for patient moni­
toring. 
Sensor 	connector standardization. 
Positive control of IV fluid dispensing. 
Sensor materials and attachment require­
ments study. 
Standard measurements lists; standard 
derivations, terminology, etc. for patient 
monitoring. 
Evaluation and development of automated 
urinalysis techniques. 
Analysis of phenolic compounds (natural 
products, drugs, drug metabolites) of 
clinical interest. 
Day/night monitoring of patients require­
ing real-time or near-real-time unobtru­
sive surveillance. 
Odor controlled waste collection system for 
colostomy and Ileostomy patients requiring 
surgical appliances. 
Urine collection and measurement. (Ref. 
CCN to Contract AASW 2073 - Proposal 
F32012). 
11-20 
The following paragraphs explain in more detail what the recommendations involve, how 
they could be useful, and the schedules for their implementation. The cost estimates are 
included in Paragraph I1B-6.0 of this Final Report Supplement. 
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5.1 COMBINED PATIENT MONITORING SYSTEMS 
1L Introduction 
During the survey of the hospitals participating in this study, three computer 
program systems for handling patient monitoring applications were studied. 
These programs were developed under federal grants. It was found that each 
program system was well advanced in the specific areas for which it was de­
signed, however the design goals were not identical. The differences were 
medically compatible with each other but of variant application; that is, one 
contained pulmonary measurements, another contained screening routines, and 
still another contained infusion techniques, etc. Also, the programs were writ­
ten on two different types of computers, (the CDC 3200/3300 and the IBM 1800) 
and were written in different languages (FORTRAN and Assembly). 
2. Unique Advanced Technology 
A uniquely powerful patient monitoring program system could be created from 
these existing programs. This could be done by combining the three programs 
into one. The specialized, highly developed functions unique to each program 
would be lifted out and integrated into one overall system. System optimization 
would be engineered. Redundant, overlapping functions would be eliminated. 
Routines that perform essentially the same function would be evaluated and only 
the most efficient of these routines would be used. Also, routines which are of 
specialized use to research institutes but not of general application to clinics 
and hospitals would not be included. Complete documentation of the three systems 
would be produced plus the documentation describing the combined system. 
The hospital functional areas serviced by such a combined system would include: 
screening
 
catheterization labs
 
x-ray labs
 
operating rooms
 
intensive care units
 
cardiac care units
 
exercise labs
 
rehabilitiation facilities
 
The overall physiological measurement areas for monitoring would include: 
cardiovascular 
pulmonary 
temperature 
blood chemistry 
urine and post operative thoracic fluid drainage 
fluid infusions 
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The combined measured and derived parameters that could be obtained from 
this system might include those parameters listed in Table IIB-1. In develop­
ing such a system, a number of steps would be required beginning with an 
initial evaluation of the three systems. This involves: 
a. Studying the current technical documentation describing the programs. 
(NOTE: It is understood from conversations with the hospitals using 
these programs that this type documentation is essentially non­
existent.) 
b. Studying and documenting the programs under the advice of consultants 
from the host hospitals. This includes gaining an understanding of 
and the documentation of the overall structure of the program system, 
the individual functions of the program, the algorithms making up the 
functions, the program coding in many instances, and the functional 
timing interfaces between the various parts of the programs. 
Once this basic overall and detailed understanding had been gained and documenta­
tion of the three systems has been reviewed, the next step would entail the se­
lection of those patient monitoring functions generally applicable to non-research 
hospitals and clinics. This could be done in conjunction with the host hospital's 
consultation with the contractor team. 
After the functions had been selected that would make up the combined patient 
monitoring system, then the overall program design would be made. This design 
would integrate existing functional blocks of coding into a total program system. 
Once this basic system had been assembled, integrated and coded, it would have 
to be debugged and checked out on a computer. Once all this work was complete 
the system would be clinically evaluated by a team consisting of a host hospital 
and the contractor. 
Thus, produced at this time would be a uniquely powerful patient monitoring 
system that was engineered for efficiency and applicability to hospitals and 
clinics (not necessarily of a research orientation). This system would have been 
derived from the best possible combinations of functions of three thoroughly 
proven, eminent, and successful existing systems. 
A follow-through phase, which is not part of this R&D task, would involve the 
conversion, checkout, system augmentation/interfacing, and operator training 
for a host hospital or clinic desirous of adopting this newly combined system 
for their use. 
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TABLE IIA-1. COMBINED MEASURED/DERIVED PARAMETERS (Continued) 
2. PULMONARY 4. BLOOD CHEMISTRY 
respiration amplitude artetial blood bicarbonate 
respiratory rate venous blood bicarbonate 
forced vital capacity blood analysis 
max. expiratory flow rate blood oxygen concentration 
one second expiratory volume 5. URINE 
maximum instantaneous respiratory pressure 
urine output volume and raterespiratory minute volume 
tidal volume 6. OTHER 
respiratory work, inspiration measurement of empty blood unit 
respiratory work, expiration chest drainage fluid volume and rate 
lung compliance 
oxygen uptake 
respiratory quotient 
respiratory resistance 
3. TEMPERATURE 
central and extremity temperature 
TABLE IIA-I. COMBINED MEASURED/DERIVED PARAMETERS
 
CARDIO- VASCULAR 
heart rate 
stroke volume 
cardiac output 
duration of systole ejection 
peripheral resistance 
systolic pressure 
diastolic pressure 
mean venous pressure 
electrocardiogram signals 
vector cardiogram signals 
mitral Insufficiency Index 
appearance time 
buildup time 
mean circulation time 
central blood volume 
cardiac index 
average arterial pressure 
pulse deficit 
premature beat rate 
arterial pressure first derivative 
premature ventricular contraction 
arrhythmia (premature & widened beat) 
left atrial pressure 
densitometer calibration 
superior vena cava %osaturation 
mid right atrium % saturation 
pulmonary artery trunk % saturation 
pulmonary artery wedge %saturation 
radial artery % saturation 
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5.2 EVALUATION OF SIGNIFICANT PARAMETERS OF EXISTING MEDICAL EQUIPMENT 
i. 	 Explanation of the Technology 
The evaluation of significant parameters relates to product effectiveness tech­
nology whith provides an overall measure of the degree to which a product or 
system achieves a specified value criterion. This technology considers not only 
performance, but also reliability, safety, maintainability, and availability. The 
application of this technology permits an objective trade-off of these parameters 
versus 	relative cost. As applied in the health care environment, this technology 
would permit the hospital or other health care facility to predetermine the relative 
merits of competing products or systems. These evaluations then form the basis 
for health care management decisions relative to product and/or system procure­
ment. 
2. 	 Uniqueness of the Technology 
Many management techniques exist which provide a basis for cost trade-off 
against single value criterion elements. Thus, evaluations of performance versus 
cost, reliability versus cost, safety versus cost, etc. are relatively common. 
The effectiveness technology was developed in the aerospace industry to combine 
the various value criteria elements into a single index for systems-efforts. At 
GE-RESD the effectiveness technology development has recognized that the value 
criterion can be partitioned into elements other than or in addition to the more 
conventional elements. Hence, the technology as applied possesses a high degree 
of flexibility to enable adaptation to virtually any situation. 
3. 	 End Products 
There will be two end products resultant from the research and development task 
described herein. The first end product will be a technology utilization manual 
which will enable health care system management to apply to effectiveness tech­
nology as a tool for making management decisions for the acquisition of products 
and/or systems. The second end product will be a separate appendix to the tech­
nology utilization manual which will compare the specific products and systems 
selected for the technology demonstration in the study. The latter manual can 
serve as an immediate guide to hospital management in the selection of cur­
rently 	available products and systems. 
4. 	 Recommended Program 
The recommended program would be accomplished in six interrelated steps: 
a. 	 Select at least three products (for example arrhythmia detector, 
electric bed and X-ray) and one system (for example, a typical four 
or eight patient monitoring system); and develop the specific value 
criteria elements. 
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b. 	 Develop the effectiveness models for the products and system(s) 
selected.
 
c. 	 Develop data sources to be utilized in exercising the models. 
d. 	 Exercise the effectiveness models and develop the figures of merit. 
e. 	 Prepare the technology utilization manual appendix which compares 
specific products and systems. 
f. 	 Prepare the technology utilization manual which will permit the ap­
plication of the effectiveness technology by health care systems 
management. 
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5.3 	 PATIENT MONITORING USING TELEMETRY TECHNIQUES 
1. 	 Explanation of the Technology 
Small, light transducer-transmitter units are needed to monitor physiological 
parameters during unrestricted. normal activity or during rehabilitating exercise. 
They free the patient from lead connections, ensure safety from dangerous electri­
cal currents and enhance comfort for the ambulatory patient. The use of telemetry 
in monitoring physiological data has widespread application and opens up new and 
lifesaving possibilities in modern health and emergency services. Some of the 
applications are: 
A. 	 In Hospitals 
1. 	 For ambulatory patients 
2. 	 In surgery (NASA SP-5023, p. 11) 
3. 	 In intensive care units (NASA SP-5023, p. 5) 
4. 	 In the rehabilitation unit 
B. 	 For Out Patients 
1. 	 For patients during recovery from disease 
2. 	 For patients having diseases in a dormant state, but who need advanced 
warning of acute attacks (cardiac problems, epilepsy, diabetes) 
3. 	 For patients under diagnostic observation 
C. 	 Emergency Cases 
1. 	 At the place of the event 
2. 	 During transit in the ambulance 
Small, light transducers and transmitters are desirable. These items would 
measure physiological parameters, transmitting the data to data receivers, pro­
cessors and/or display units which may be located at distances ranging from a 
few feet to a few miles from the patient. The transmission mode would not involve 
physical linkage between the patient and the data center. 
A microminiature transmitter-temperature sensor unit was developed during the 
biosatellite program. The temperature sensor and transmitter unit is . 6 inches 
in diameter, .2 inches thick and weighs 4 g. It is powered by a mercury cell. 
NASA personnel (AMES Research Center) have carried this development further 
by microminiaturizing signal conditioning and processing circuitry. 
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These devices provide a basis for the development of similar devices which will 
measure other parameters. Some important parameters for observation and trans­
mission listed below: 
1. 	 Temperature 
2. 	 Blood Pressure 
3. 	 EEG 
4. 	 Diabetic Shock Monitoring 
5. 	 Arrhythmia Detector Based on EKG 
6. 	 Others - See R. S. Mackay, Bio-Medical Telemetry, for an exhaustive list 
of uses for transducer-telemetry systems. 
Besides the selection design, and microminiaturization of the appropriate 
circuitry compatible with selected transducers such problems as artifacts 
through patient mobility, uniform radiation coupling to local receiver, 
elimination of RF interference, etc. must be overcome. 
2. 	 Uniqueness of the Technology 
Virtually all of the parameters mentioned above are routinely monitored for hos­
pital patients having severe problems. Relatively small transmitter units for 
physiological telemetry are commercially available, for some applications. The 
uniqueness of the suggested technology is the proposed development of an assembly 
of transducers, transmitters and some degree .of signal conditioning and pre­
processing into a microminiature device which can be attached to the patient with 
the least amount of discomfort. In addition, the monitoring and/or recording per­
iod may be controlled by an event sensor, which if so desired, can act as an in­
formation valve limiting the information flow to periods selected by events of pre­
determined interest. Thus, monitoring may be extended to ambulatory patients, 
both in and out of hospitals. However, certain of these technological advances, 
largely developed on NASA programs have been employed on a limited basis by 
numbers of medical investigators who have assimilated these techniques into their 
own areas for the past several years. Implementation for the purposes mentioned 
below appears relatively straightforward. 
3. 	 End Products 
The end products Involve two separate aspects leading to broad application in 
patient monitoring: 
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1. 	 Microminiature sensor-transmitter signal conditioning packages which can 
be implanted or strapped to patients. Here, the blood pressure sensor 
and improved EKG sensor are problably most important from the monitor­
ing point of view. 
2. 	 The design of automated data handling techniques which will sift the data 
gathered for important signs (abnormalities) and then send warnings, etc. 
This insures that the data center is not bogged down in gathering, storing 
and displaying masses of essentially ordinary data. Most physiological 
parameters are not significant unless they exceed certain bounds. 
4. Recommended Program 
An initial program is recommended to define candidate systems which are to be 
developed for the monitoring of physiological parameters within and outside of 
the hospital environment by telemetry techniques. 
Following an extensive requirements and applications survey, candidate systems 
for monitoring individual or a multiplicity of physiological parameters, will be 
breadboarded and evaluated with animals as a separate task. Ultimate selection 
of systems for prototype development and human trials will be based upon this 
study. 
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5,4 ANALYSIS TECHNIQUES FOR ECG, ARRHYTHMIA DETECTION AND CLASSIFICATION 
EXPLANATION OF THE TECHNOLOGY 
Several computer codes are available which permit, to some degree, automated analysis of 
ECG and the detection and classification of arrhythmia. However, the various signal leads 
show considerable variation between different patients which makes the application of auto­
matic methods extremely difficult. Variations in lead configuration, analytical programs 
and monitor hardware exist. To make automated computer analysis of cardiac patients 
extensively available and similar (if not identical), combinations of program functions 
and techniques, VCG processing and other physical phenomena should be explored. An 
optimized program, incorporating techniques of the various ECG programs may be develop­
ed, in parallel with development of other technique. Optical data analysis may prove to be 
advantageously employed for the characterization of the ECG/VCG complexes of interest. 
For example optical Fourier Analysis can be carried out in nearly real time without the 
use of an expensive large scale computer. 
UNIQUENESS OF THE TECHNOLOGY 
The suggested technology is unique in that it involves the combined use of ECG signals and 
other physical measurements such as the reflection or absorption of pulsed electro­
magnetic energy which may depend on the polarization or depolarization process of the 
heart muscle. In addition optical methods for data processing are relatively new and so 
far, to the knowledge of the author, have not been explored for their potential use in ECG 
evaluation or arrhythmia detection or classification. Additionally, a systematic approach 
to analysis and integration of the many independantly developed, not fully disseminated 
programs will assist in channelling activities in a common direction. 
END PRODUCT 
The end product will be a universally applicable ECG monitor and analysis program, 
definition of recommendatiohs for an improved method to detect the depolarization and 
polarization phenomena throughout the heart wall, and analysis of optical analyzer to 
characterize the polarization and depolarization signals through their Fourier spectrum. 
RE COMMENDED PROGRAM 
It is recommended that a survey and analysis be carried out of all existing schemes which 
are presently being used to analyze ECG/VCG or to detect and classify arrhythmias. Re­
quirements will be defined from the analysis of information obtained from selected medical 
centers and institutes and from analysis of existing software techniques. Recommendations 
for meeting these requirements will be made by outlining one or several approaches using 
advanced technology. Subsequent activity will include development of an integrated software 
progranf and application of new hardware techniques. 
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5.5 	 RESPIRATORY ANALYSIS 
EXPLANATION OF TECHNOLOGY 
The pulmonary system is presently the subject of intense interest. Among the reasons 
for this are: 
A. 	 The expoloration of hostile environments such as the oceans and space, in which 
artificial atmospheres having abnormal gas composition and pressures are 
utilized; 
B. 	 The increasing incidence of primary pulmonary diseases such as emphysema, 
asthma, cystic fibrosis, and lung cancer, as well as pulmonary complications 
due to cardiovascular diseases. 
New approaches are needed for the rapid screening of the population for evidence of 
pulmonary disease, the diagnosis of specific diseases, and the monitoring of pulmonary 
patients. 
The pulmonary system is concerned with the transfer df certain gases between the external 
atmosphere and the blood. As such, pulmonary abnormalities may involve: 
A. 	 Inadequate movement of air into the lungs (i. e., abnormal ventilation, due to 
changes in the mechanical properties of the lung or its supporting muscles. 
B. 	 Destructive changes in the membrane which separates the air and blood sides 
of the lung and thus decreases gas diffusion. 
C. 	 Inadequate flow of blood through the lungs (i.e., abnormal perfusion). 
The assessment of these three types of abnormalities involves different types of measure­
ments. Tests of ventilatory function generally involve measurements of mechanical fac­
tors such as total volumes of gas breathed per breath or per unit time; pressure-volume 
flow rate - time correlations; and velocity-time correlations. In such measurements, the 
patient breathes in a specified manner and the data is recorded either in the vicinity of the 
nose or mouth, or from each lung separately (bronchospirometry). 
The functioning of the membrane and pulmonary circulation generally measured by cheni­
cal analysis of the gas breathed, or by chemical analysis of the blood. That is, composi­
tions 	of gas inhaled and exhaled, and 02 and C02 saturations and pH in the blood are 
needed. 
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UNIQUE TECHNOLOGY 
Recent technology makes possible the advancement of present pulmonary measurement 
techniques. Examples of possible improvements are: 
A. 	 Improved data analysis of present instruments such as the spirometer. 
B. 	 New instruments which, for example, "drive" the lungs with forced breathing 
at various frequencies, thus enabling information regarding the location of 
abnormalities to be gathered. The frequency response of the lungs is markedly 
effected by the physical state of the lung tissues, thus enabling various diseased 
conditions to be uncovered and diagnosed. Furthermore, the reflection of 
pulses sent into the lungs gives clues as to the location and extent of ventilatory 
abnormalities. 
C. 	 Improvements in gas analysis which will allow more accurate and rapid measure­
ments to be taken. Particularly important is a unit which is small enough to 
become part of a body transducer system. 
NASA has developed a small mass spectrometer for the dynamic analysis of alveolar 
samples. Mass spectrometers using radio-frequency quadrupole fields can be miniaturized 
so that they become suitable for continuous patient monitoring. An R and D program is 
required to meet clinical requirements and safety standards. GE's R and D center has 
developed a three-dimensional quadrapole mass spectrometer of unusual simplicity which 
could be used as a point of departure. 
END 	PRODUCT 
A report of the state-of-the-art of respiratory monitor equipment and techniques including 
evaluation of existing (in-use or developmental) approaches and recommendation for design 
and/or modification of an optimized system resulting from requirements defined during 
this effort. 
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5.6 	 AMPLIFIER AND SIGNAL CONDITIONER STANDARD REQUIREMENTS
 
SPECIFICATION
 
Investigate availability and capabilities of standard amplifiers - signal conditioners, i.e., 
modules with selectable input/output impedance, gain change, etc., such that they are 
adaptable and interchangeable as well as cost effective. Generate requirements for 
desirable units. 
The work tasks for completing this project involves the surveying of equipment in use 
as well as evaluating that equipment. The manufacturers of the equipment must be con­
tacted and determine the equipment that is either in design or is already available. A pre­
liminary specification will have to be generated to define the requirements. Al this 
effort should then be reviewed and discussed at this point. The results from this review 
will be used to update the specification and would then be issued to industry for comment. 
Applicable comments from-industry would then be screened and used to update the specifica­
tion. An equipment listing and a vendor listing would be then generated. Periodic and a 
final report should also be issued. 
The following Schedule Planning Sheet outlines the estimated schedule. 
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5,7 	 NARROW BAND VIDEO SYSTEMS FOR REMOTE PATIENT MONITORING, 
CONSULTATION, AND DIAGNOSIS 
1. INTRODUCTION 
It has been generally accepted that video systems can play a basic part in the health field 
for both remote observation of patients and for access to diagnostic measurements, tables 
and files of symptomology when consultation and personal presenbe is not available. 
Examples of such instances include remote clinic operations in rural and ghetto areas, 
disaster area and shipboard emergencies, first aid, and anywhere where medical assist­
ance is limited. 
The systems should be adaptable so that consultants in one field can consult with specialists 
in allied fields, or in the same field to give support to their diagnoses. 
With the widespread use of such video systems in conjunction with physiological data 
systems, it can be foreseen that not only will the physicians and patients benefit, but 
monitoring physicians can continue their association and education with their procedures 
transmitted and discussed. Recordings of the transmissions including both video and 
related data will form a bank of medical information for future review by students and 
practitioners. The technique may be used in some cases to accelerate the student's 
exposure to a large cross section of cases, and thus to broaden his education. 
However, normal video signals require a wideband transmission media of the order of 
4-8 MHz bandwidth, such as a coaxial cable or microwave circuit. These media are 
costly, and require special semi-permanent installation. It should therefore be a design 
objective that the video be transmitted over inexpensive telephone circuits and provide a 
close man-machine relationship between patients, paramedics, physicians and consultants; 
this objective, moreover, must be realized taking into account the requirements of 
resolution, must be realized taking into account the requirements of resolution, grey 
scale 	or color quality, and commercial error rates, over all available communications 
media including cable, microwave and satellite. 
2. RECOMMENDED DESIGN STUDY APPROACH 
For the purpose of explanation, bandwidth can be expressed by the relation: 
of grey or Frame Bandwidth o< *Noof picture) x /No.( color levels x (Rate }elements 
The number of picture elements and the number of grey or color levels required for 
medical purposes shall be a subset of this study; however, it may be assumed that the 
minimum requirements are comparable with commercial television standards. Accord­
ingly, 	 for bandwidth reduction it is considered that the frame rate is the prime candidate 
for achieving the design goals. 
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Techniques are available for implementing reduced fraur rate video including: 
a. At the transmitting end: -
Slowspeed scan cameras
 
Storage tube converters with standard cameras
 
Sampling scan converters with standard cameras
 
b. At the receiving end: -
Storage monitor CRT's each with one standard monitor.
 
Storage tube scan converters with standard monitors.
 
Magnetic disc scan converters with standard monitors.
 
According to available information, "snap-shot" representation with a new frame displayed 
acceptable designinstantaneously on the order of once every 10 seconds may be an 
approach for medical video systems. 
3. RECOMMENDED TASK 
It is recommended that a technical and clinical evaluation be held to identify a practical 
narrow band video system for the health field within the current state-of­cost-effective, 

the-art, and to establish subjective signal-to-noise and resolution standards for such a
 
system. 
Selected equipment will enable a comparison to be made between the performance 
of: 
Slow scan camera versus storage tube transmission, and1. 
Storage tube versus magnetic disc scan conversion.2. 
The evaluation should not however by limited to the compatabflity above 
described; any 
other equipment identified as being applicable would be evaluated 
by mutual agreement. 
shown in the attached schedule An implementation Plan for the proposed evaluation is 

planning sheet.
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TABLE IIA-2 
TYPICAL TRANSMISSION & RECEPTION EQUIPMENT 
(A) 	 Transmission Equipment 
Based upon a 1 in 10 frame rate, the following transmission equipment is 
available for use, either in development or production state: 
1. Slow Scan TV Cameras 
Most vidicon cameras can be used for slow
 
scan transmission, however with modifications
 
to the deflection system.
 
For special high resolution the General Electric 
I" (Z7872, Z7873 and Z7894) and 1 1/2'
 
(Z 7921 and Z7940) FPS Vidicons are available
 
with magnetic, electrostatic or hybrid deflection
 
and focusing designed for military and space
 
cameras. These tubes have been used for up to
 
1600 lines resolution in the focus projection and
 
scanning mode.
 
The RCA 1" (RCA-7735) Vidicons are specified 
for resolutions up to 900 lines. 
A review will be made to determine applicability
 
of these tubes with the necessary modifications
 
for their use in commercial cameras.
 
2. Storage Tube Converters 
(a) 	 Marconi 3V21 camera capable of 800 lines
 
resolution at the center and 650 lines at the
 
corners of the picture, and standard sweeps
 
of 525 and 800 lines, modified with a
 
Westinghouse Permachron Tube WX-5123
 
(b) 	 Standard Vidicon camera GE-TE33; and
 
Princeton Electronic Products PEP400
 
storage terminal using a Lithicon storage
 
tube. The tube has a resolution of 800
 
or 1200 lines.
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3. 	 Magnetic Disc Converters 
Standard Vidicon Camera GE-TE33; and
 
Colorado Video Magnetic Disc 220B to convert
 
525 line video to slow scan video with select­
able bandwidth of 8, 4, 2, 1 or 0.5 KHz
 
4. 	 Sampling Scan Converters 
Standard Vidicon Camera GE-TE33; and
 
Colorado Video Converter/transmitter VC201B
 
which compresses the video bandwidth to the
 
audio range of 8, 4, 2, 1 or 0.5 lHz as desired.
 
Time taken to reproduce a single frame will vary
 
from 7 seconds to 2 minutes according to the
 
bandwidth selected.
 
(B) Reception Equipment 
Video processing equipment to receive the slow scan video 
and 	convert it to 30 frames/see. 525 line or 800 line video 
for 	display on standard video monitors. 
1. 	 Princeton Electronics Storage Tube Scan Converter
 
PEP 400, using a Lithicon storage tube (See 3.2
 
above) for storage of the incoming video at slow
 
rate and simultaneous playback at conventional rates.
 
A separate converter is required for each video
 
channel. 
2. 	 Colorado Video Magnetic Disc Scan Converter 220B,
 
using a rotating video memory disc to store the
 
sampled picture with a frame rate of between 4
 
seconds and 2 minutes. The converter is available
 
in one, two, three and four channel versions.
 
3. 	 Data Disc Video Disc Files capable of storing up to
 
600 images from the disc's 600 separate tracks.
 
Is designed specifically for pulsed and time-lapsed
 
fluoroscopy including instant history, image
 
subtraction and animation. 
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RECEIVING END:TRANSMITTING END: 
1. 	 SLOW SCAN 
MODIFIED
 
VIDICON
 
2. STORAGE TUBE 
CONVEPTERS 1. STORAGE TUBE 
SCAN CONVERTERS 
A. 	 STANDARD VIDICON WITH 
LITHOCON VIDEOLITHOCON STORAGE TUBE OR 	 STORAGE MONITOR 
TUBEB. 	 MODIFIED CAMERA WITH 
PERMACHRON STORAGE TUBE 
2. 	 STORAGE DISC 
SCAN CONVERTERS3. 	 MAGNETIC DISC CONVERTERS 
GNETIC 
DISC 220B 
STANDARD 
VIDICON 
SOAE4
 
awVIDEO 
MONITOR!4. SAMPLE SCAN 
CONVERTERS 
VIDEO CONVE1 TEE 
02 1B 
_ 
STANDARD 
VID)ICON 
Figure IIA-9. Transmitting and Receiving Equipment 
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5.8 NON-INVASIVE TECHNIQUES FOR PATIENT MONITORING 
EXPLANATION OF THE TECHNOLOGY 
There is a great need for non-invasive techniques to measure such physiological parameters 
as central and peripheral blood flow velocity, volume rate, stroke volume, ventricular 
chamber volume, blood distribution, ventricular, arterial and venous pressure, arterial 
and ventricular compliance, myocardial contractility and so forth. Present techniques 
to obtain a direct measurement or indirect physiological parameters from which the 
parameter of interest can be derived frequently require catherization, arterial cut down 
and other invasive procedures. These measurements, therefore, require high skills 
and produce discomfort to the patient who frequently must be immobilized. Additionally, 
problems of blood clotting, interface leakages and infection are encountered. 
There are a number of physical methods which are basically non-invasive and do not require 
catherization or the injection of contrast materials, such methods are 
1. Ultrasonic measurements 
2. Recording of passive sounds and vibrations 
3. Measurements of thermal gradients 
4. Impedance measurements 
5. Plethysmographic methods 
6. Colorimetric measurements and so forth. 
The use of these methods to measure some of the mentioned physiological parameters is 
complicated by the difficulty of controlling artifacts which are introduced by the remoteness 
of the measurement and the external environment. In addition, remoteness permits physio­
logical noise to be collected which must be dealt with so that the wanted signal can be inter­
preted. 
UNIQUENESS OF THE TECHNOLOGY 
NASA developments contributed heavily to the advancement of non-invasive techniques (for 
example, NASA SP-5041, NASA SP-5054, NASA SP-5023). Presently many bio-engineering 
The need for stepping back and looking atorganizations are engaged in just such programs. 

the basic ommon problems which are associated with all these techniques is now in order.
 
From such an evaluation reflected against our present technological background, one may
 
expect the definition of the major problems and recommendation for their solutions.
 
END PRODUCT
 
The product of this program will be an exhaustive discussion of non-invasive techniques 
or medical centers, with recommenda­presently under consideration or in use in hospitals 
tion and suggestions or how to solve some of the Inherent difficulties associated with these 
methods. Follow-on activity would include design, breadboard and test of candidate systems 
leading to demonstration prototypes for clinical evaluation. 
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RECOMMENDED PROGRAM 
Institute medical center contact and survey. Establish requirements and determine the 
efficacy and problems associated with equipment in use. 
Analyze the commonality of problems associated with existing equipment and other ideas 
presently under consideration. 
Prepare suggestions and recommendations for their solution. Proceed with hardware 
development of selected devices and techniques as a follow-on phase to this task. 
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5,9 SENSOR CONNECTOR STANDARDIZATION 
EXPLANATION OF TECHNOLOGY 
There are a multitude of physiologic sensor connectors marketed today of various types
and configurations. The dissimilarity of connectors presents difficulties in application of 
various sensor leads and monitoring equipment. Physicians have preferences for sensors, 
cables and monitor equipment which often are incompatible from the connector aspect. 
Additionally, equipment available at the medical center (existing or newly purchased) often 
must be modified to enable interconnection in a desired configuration. 
UNIQUENESS OF TECHNOLOGY 
Application of a single source systems engineering approach to optimizing connector 
design both from a fit and functional standpoint, and the issue of a specification to which 
these connectors may be produced will be unique in the medical hardware area and hope­
fully would initiate action to create similar standards for other equipment and interfaces. 
END PRODUCTS 
The end product of this effort would include a Medical Systems Connector Standard, opti­
mized connector designs and a recommended source tabulation including connector 
description, application and qualified vendors. 
RECOMMENDED PROGRAM 
Initiate those tasks delineated in the schedule planning sheet attached, leading to the issue 
of a standards document to industry. As a result of this task, additional effort may be 
undertaken to evaluate industry response, test responsive products and issue approved 
source lists. 
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5.10 POSITIVE CONTROL OF IV FLUID DISPENSING 
Investigate and demonstrate non-gravity techniques of IV fluid dispensing - to avoid holding 
or hanging of bottles and bags, etc. and develop a better means for controlled infusion. 
One system recently developed by a southern university in response to needs of medical 
profession uses plastic bags compressed by negator springs. An interesting alternate is 
a double bag with a gas cartridge. See the diagram below. 
F FLUID BAG 
MINIATURE FLOW CONTROL VALVE;
 
MINIATURE PRESSURE REGULATOR EMERGENCY CAN BE HELD
PRESSREREGLATO 
AND VENT WITH MINIATURE GAS 	 UP, SQUEEZED, ROLLED, ETC. 
CARTRIDGE (OR ANY GAS SUPPLY). 	 TO SE R L D,TO TRANSFER FLUID.) 
The work items involved in order to accomplish the program for investigating non-gravity 
techniques of IV fluid dispensing involves the evaluation of existing alternate means. This 
would be followed by evaluating the need vs approximate costs and the accompanying trade­
off. The requirements would have to be defined followed by the fabrication and testing of 
a prototype. The system should be then reviewed and critiqued. A detailed specification 
would then be issued which contains the findings above, plus the building of a demonstration 
unit. 
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5.11 SENSOR MATERIALS AND ATTACHMENT REQUIREMENTS STUDY 
Investigate, develop and document requirements for sensor materials and attachment 
(sensor - patient, interface) techniques with intent of promulgating standardization and 
providing producibility effort to expedite availability of "production" items. 
Determine optimum size, shape and materials for various sensors (evaluate multitude 
now available and proposed items). 
Define, develop and document attachment requirements and existing techniques for long 
term, short term, disabled, ambulatory and exercise type applications. 
EXAMPLE:
 
EEG sensor fastened by Velcro to a shaped inflatable belt that provides both placement 
and pressure; consider effect of pressure on respiration and subsequent interpretation of 
data. 
LEADSBAK 
IJECTRODES (VELCRO 
INFLATABLE WITH I 
BODY VELCRO INNER-
CROESS OTION FACE 
AA-A 
STRAPS 
The work tasks involved in executing the above will involve a number of tasks stated in the 
following. Surveys of utilization and manufacturer should be made. The definition of 
requirements should be developed with an accompanying task review and discussion. From 
this the requirements document would be updated. A test prototype system should then be 
fabricated. This system should be tested and documented. 
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5.12 	 STANDARD MEASUREMENTS LISTS, STANDARD DERIVATIONS, TERMINOLOGY, 
ETC., FOR PATIENT MONITORING 
Accomplish the documentation (and/or development) of measurement lists, standard 
derivations, terminology, etc., including dimensions and "conditions" under which they 
are valid for application to patient monitoring data processing and handling. 
For example there are about nine formulas for determining body volume from weight and 
height (body volume is used for example in determination of cardiac index) - the hardware 
-and software designers need be told which formula is required to be used for each particu­
lar calculation. 
The work tasks for executing the project are as follows: 
review data derivations (via tests, advisory committee, consulting doctors) 
expand patient monitoring system measurement list definition for derivations 
delineate measurement methology - computational methodologies and variations 
detail evaluation of sample rates, accuracies, etc., for each patient monitoring 
system application 
update measurement list for specifications per (4) 
- provide initial data processing and handling specification criteria 
- periodic reports 
- final report 
The following Schedule Planning Sheet outlines the estimated schedule. 
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5.13 	 A STUDY TASK LEADING TO EVALUATION OF THE PACE/RHO AUTOMATIC 
URINE ANALYSIS EQUIPMENT FOR CLINICAL APPLICATION 
1.0 INTRODUCTION 
The Pace/Rho system was designed to provide real time analysis of urinary calcium, 
creatine and creatinine during the 30 day Mission of the Biosatellite. 
2.0 UNIQUE TECHNOLOGY 
This system (11. 75 long x 5.5" high x 6.0" deep) contained a fluid handling block; calcium 
analyzer; creatinine-creatine analyzer; reagent reservoirs, reagents; calibration fluid 
reservoirs; optical read out unit; metering pumps; pressure regulator; timers; and 
associated electronic equipment (Figure XIV-I). 
Two milliliter alliquots of urine were sequentially analyzed according to a pre-determined 
schedule or on command from a ground station. Data transmitted included the concentra­
tions and temperature of calcium, creatine and creatinine, the number of samples and 
dilutions, and engineering status (power, lamps, interinal temperature and pressure). In 
addition, provisions was made for flushes between samples and automatic calibration with 
pre-loaded calibration fluids. 
Based on the compactness of this unit and its flight proven reliability, it would be of 
interest to investigate application of the automated Pace/Rho urine analysis techniques to 
analyses of clinical interest. This would include those normally accomplished on a 
"routine" basis in clinical chemistry laboratories as well as specialized analyses required 
for research activities. Initial emphasis would be placed on urine analysis but may later 
be extended to include blood serum analysis. 
3.0 PRELIMINARY STUDIES AND GOALS 
An initial program would include survey and evaluation of requirements for manual and 
automatic urine analysis. Emphasis would be placed on comparing specifications of avail­
able manual instrumentation and evaluation of adopting and integrating that methodology, 
identifying specific tests and techniques which appear amendable to the automated Pace/Rho 
approach. Application of membrane technology, toxicity studies, electrode separation 
techniques and related methods will be evaluated in conjunction with the automated colori­
metric techniques employed in the Biosatellite system for application to a urinalysis system 
for patient monitoring. Blood serum analysis capabilities will also be evaluated. 
Breadboarding of the Pace/Rho equipment, for analysis of other than that for which it 
was originally intended (calcium; creatinine/creatine), cannot be justified in advance of 
conducting surveys to identify analytical procedures amicable to this type instrumentation 
and modifications. In addition, it will be necessary to concurrently identify the most sig­
nificant parameters that clinicians consider obligatory to monitor in certain patient types 
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on a near real time basis. This combination of information will make it possible to 
recommend a logical plan for breadboarding and testing advanced concepts of the Pace/Rho 
urine analysis equipment suitable for patient monitoring. 
The Pace/Rho equipment, as designed for the Bio-satellite program, contains a logic sys­
tem suitable for delivering specific volumes of reagents (picric acid, sodium hydroxide, 
sulfuric acid, hydrochloric acid, calcium reagent) on a programmed schedule. Other tests 
for example, uric acid, urea nitrogen, choride, sodium, potassium, steroid hormones, 
lactic acid, catecholamines, PSP excretion, etc., require different reagents, sample 
dilution incubation for varying periods of time, and an optimal readout system required 
for a specific test. In this instance the spectoal response characteristic of the photo diode 
suitable for the analysis of creatinine/creatine, in all probability, would not be suitable for 
a number of the tests above. Certainly, if we were monitoring urine on a near real time 
basis for catecholamines as five-hydroxytryptamine, florescence would be the readout 
system of choice. If other analysis were being done concurrently; ultraviolet, visable, or 
infra red spectro-photometric readout systems might be required. 
Advanced surveys, as recommended, would also investigate possible applications of the 
Pace/Rho instrumentation, with appropriate modifications, for the analysis of serum 
samples. Serum analyses, however, frequently are a problem unto themselves, and a 
breadboard suitable for urine chemistry would probably require further modifications for 
serum. 
In summary, thorough surveys of clinical laboratories (mail, surveys, and personal inter­
views) plus a comprehensive literature search, are deemed requisite to planning bread­
board studies for patient monitoring applications of the Pace/Rho urine analysis equipment. 
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5.14 ANALYSIS OF PHENOLIC COMPOUNDS OF CLINICAL INTEREST 
INTRODUCTION 
NASA specifications for fuel cell derived potable water in the Biosatellite Program called 
for the total phenol concentration not to exceed one (1. 0) part per billion (ppb). Methods 
of analysis available, including the Standard Methods( 1 ) procedure, lacked accuracy and 
precision, or were too time consuming to insure a completed analysis within 30 minutes of 
launch. 
For this reason it was considered essential to develop methodology which would permit 
analysis with a high degree of confidence at the 1.0 ppb level within the allotted time limit. 
UNIQUE TECHNOLOGY 
The method of choice resulting from this effort is based upon continuous liquid-liquid 
extraction of aqueous samples with diethyl ether and the elimination of interfering substances 
by the selective partitioning of phenols into the ether phase(2 ). 
These are separated from the ether as lithium phenolates with lithium hydroxide and re­
converted to phenols with hydrochloric acid in a volume of deionized water equivalent to 
the original volume of the sample (100 ml). Analysis is achieved by treating the aqueous 
mixture of phenols with a modification of the 4-aminoantipyrine/potassium ferricyanide 
reagents and comparing a chloroform extract of the 4-aminoantipyrine dye complex with an 
appropriate standard in a spectrophotometer at 458 nanometers. 
Reduction of the concentration of 4-aminoantipyrine from 60 p moles to 40 A moles per 
test significantly reduced reagent blank color and enhanced sensitivity. This was further 
augmented by optimization of the reaction pH and final adjustment of the dye complex with 
tartaric acid buffer to pH 4.0 immediately prior to extraction with chloroform. 
Many phenolic compounds, including phenol per se and those capable of influencing the taste 
and odor of the Biosatellite water supply, e. g., 2-chlorophenol; 2, 4-dichlorophenol, 2,6­
dichlorophenol, can be detected in concentrations of 1. 0 ppb or less in approximately 20 
minutes. 
(1) 	Standard Methods for the Examination of Water & Wastewater. APHA, AWWA, & WPCF, 
514-523, 12th ed (1965). 
(2) STARKEY, R.J. & O1, E.D. Rapid Total Phenols Analysis by Liquid-Liquid Extrac­
tion with Diethyl Ether. Presented at 160th ACS Meeting, September 14, 1970. 
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For the most part phenolic compounds analyzed have been limited exclusively to contami­
nants of potable water and have not included derivatives frequently found in biological 
materials. 
The proposed study will consider application of the Biosateflite method of phenol analysis 
or modifications thereof, to the analysis of phenolic compounds found in body fluids as 
urine, feces, sputum, blood serum and gastric washings. 
New or improved methods of analysis would be of interest to clinical biochemists, physic­
logLists, pharmacologists, pathologists, toxicologists and others concerned with the fate 
and distribution of phenolic compounds in biological materials. 
END PRODUCTS 
A report delineating phenolic compounds including those found in natural products, drugs 
and drug metabollies for which analytical methodology may be significantly improved, and 
recommendations of advanced techniques applicable to these analyses. 
RECOMMENDED PROGRAM 
An extensive evaluation is required to identify phenolic compounds of clinical interest for 
which suitable analytical methodology is not available. Based upon the results of this 
study recommendations will be made to develop analytical techniques for the analysis of 
specific naturally occurring phenols; phenolic pharmaceuticals and their metabolites. Task 
outline is indicated on the accompanying schedule. 
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PRELIMINARY STUDIES AND GOALS 
An extensive evaluation is required to identify phenolic compounds of clinical interest for 
which suitable analytical methodology is not available. Based upon the results of this 
study recommendations will be made to develop analytical techniques for the analysis of 
specific naturally occurring phenols; phenolic pharmaceuticals and their metabolites. 
1.0 	 SURVEY OF STATE OF THE ART TECHNIQUES USED FOR THE ANALYSIS OF
 
PHENOLIC COMPOUNDS IN BIOLOGICAL MATERIALS
 
1.1 	 Literature survey of analytical procedures for compounds outlined in Tables
 
IHA-3 and IIA-4.
 
1.1.1 	 Wet chemistry/UV spectroscopy
 
1.1.2 	 Fluorescence spectroscopy
 
1.1.3 	 Infrared spectroscopy
 
1.1.4 	 Thin layer chromatography
 
1.1.5 	 Gas-liquid chromatography
 
1.2 	 Compile the following information:
 
1.2.1 	 Limits of sensitivity
 
1.2.2 	 Normal and pathological limits in body fluids
 
1.2.3 	 Significance and frequency of analysis in the clinical pathology
 
laboratory
 
1.2.4 	 Problems associated with interfering substances
 
1.2.5 	 Time constraints
 
1.2.6 	 Reagents required
 
1.2.7 	 Glassware required
 
1.2.8 	 Special equipment required
 
1.2.9 	 Economics of analysis
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2.0 CHOICE OF CANDIDATE COMPOUNDS
 
2.1 	 Choice of compounds for which advanced analytical methodology will be
 
developed is dependent upon the data derived from item 1. 1 and 2.2
 
2.2 	 Answers to the following questions will be documented.
 
2.2.1 	 Are there requirements for advanced analytical techniques for the
 
analysis of specific phenolic compounds for which methodology is
 
either not satisfactory or available?
 
2.2.1.1 Natiral products
 
2.2.1.2 Drugs (conventional therapeutic agents)
 
2.2.1.3 Drug metabolites
 
2.2.2 	 What other phenolic type compounds should be considered for the
 
development of analytical methodology, e. g., experimental pharma­
cological agents and their metabolites?
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TABLE I[A-3. PHENOLIC PHARMACEUTICAL PRODUCTS 
NANOMETERS 
Terramycin 390 520 
Achromycin 390 515 
Isoreserpine 390 510 
Dehydroreserpine Perchlorate 390 510 
Harmaline Hydrochloride 390 490 
Aureomycin 355 445 
Chlorpromazine 350 480 
Norharmane 350 380 
Tetradehydroreserpine Chloride 340 440 
Menadione 335 480
 
Chloroquin 335 400
 
Chlorpromazine Sulforide 335 400
 
Oxychloroquin 335 380
 
ISD* 325 465
 
Pentothal 315 530
 
Cinchonine 320 420
 
Brom ISD 315 460
 
Cinchonidine 315 445
 
Surital 310 530
 
Rescinnamine N-oxide 310 440
 
Rescinnamine 310 440
 
Salicylic Acid 310 435
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TABLE IIA-3. PHENOLIC PHARMACEUTICAL PRODUCTS (Continued) 
Rescinnamine 
Plasmoquin 
N-ethylmarmine 
p-Aaninosalicylic Acid 
Harmine 
Trimehoxycinnamic Acid 
Reserpine 
Methyl Reserpate 
Syrosingopine 
Reserpine 
Eserine 
Methyl 0-(3,5-dimethoxy 
4 hydroxybensoyl reserpate 
Adrenalin 
Norepinephrine 
Epinephrine 
Syrosingopine N-oxide 
Piperoxan 
Quinacrine 
Norhanmane 
Aflylmorphine 
Azaguanine 
NANOMETERS
 
310 
300,370 
300,365 
300 
300,365 
300 
300 
300 
300 
300 
300 
300 
295 
295 
295 
290 
290 
285,420 
285 
285 
285 

400 
530 
450 
405 
400
 
400 
375 
360 
360 
360 
360 
360 
335 
335 
335 
350 
325 
500 
380 
355 
405 
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TABLE IIA-3. PHENOLIC PHARMACEUTICAL PRODUCTS (Continued) 
Aminopterin 
Thiophenobarbital 
Methotreaxate 
Descrpidine 
Renosidine (reserpine N-oxide) 
Reserpine 
Trinethoxybenzoic Acid 
Indole 
Podophyllotoxin 
Mc Niel 

Flexin 
Neocinchophen 
Tolserol 

Procaine 

Dromoran 

Paredrin 

Neosynephrin 

Yohimbine 

Synephrin 
Phenobarbital 
Pentobarital 
Anytal 
280,370 
280 
280,375 
280 
280 
280 
280 
280 
280 
280 

280 
275,345 
280 

275 

275 

275 

270 

270 

270 
265 
265 
265 
NANOMETERS
 
460 
470 
460 
360 
360 
360 
360
 
340 
325 
320
 
320 
455 
315
 
345
 
320
 
300
 
305
 
360
 
310 
440 
440 
410 
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TABLE IA-3. PHENOLIC PHARMACEUTICAL PRODUCTS (Continued) 
NANOMETERS
 
Acetylcolchinol 265 380 
Thymol 265 300 
Quinine 250,350 450 
Note: Measurements in mu 
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TABLE IHA-4. NATURALLY OCCURRING PHENOLIC COMPOUNDS
 
FOUND IN BIOLOGICAL MATERIALS
 
5-Hydroxykynurenine 
Kynurenine 
Folinic Acid 
Thiochrome 
3-Ilydroxykynurenine 
Pteroic Acid 
Folic Acid 
p-Hydroxycinnamic Acid 
DPNH 
5-Hydroxyanthranilic Acid 
Pyridoxine 
Pyridoxamine 
Pyridoxal 
Vitamin A 
Kynurenic Acid 
Kynurenic Acid 
Uric Acid 
3-Hydroxyanthranilic Acid 
Xanthine 
Anthranilic Acid 
p-Hydroxymandelic Acid 
NANOMETERS
 
375 460
 
370 490
 
370 460
 
370 445
 
365 460
 
365 450
 
365 450
 
350 440
 
340 435
 
340 430
 
340 400
 
335 400
 
330 385
 
325 470
 
325 440
 
325 405
 
325 370
 
320 415
 
315 435
 
300 405
 
300 380
 
II-72 
TABLE IIA-4. NATURALLY OCCURRING PHENOLIC COMPOUNDS
 
FOUND IN BIOLOGICAL MATERIALS (Continued)
 
5 -Hydroxyindolenetic Acid 
Serotonin 
p-Aminobenzoic Acid 
Serotonin 
To,3opherol 
Tryptamine 
5-Hydroxyindole 
Equilih 
p-Hydroxyphenylpyruvic Acid 
Homogentisic Acid 
p-Hydroxyphenylserine 
ATP 
Adenylic Acid 
Adenosine 
Tryptophan 
Guanine 
Estradiol 

3,4-Dihydroxyphenylalanine 
Estrone 
3, 4-Dihydroxyphenethylamine 
Adrenalin 
NANOMETERS 
300 355
 
295 540
 
295 345
 
295 340
 
295 330
 
290 360
 
290 355
 
290 345,420 
290 345
 
290 340
 
290 320
 
285 395
 
285 395
 
285 395
 
285 365
 
285 365
 
285 330
 
285 325
 
285 325
 
285 325
 
285 325
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TABLE IIA-4. NATURALLY OCCURRING PHENOLIC COMPOUNDS
 
FOUND IN BIOLOGICAL MATERIALS (Continued) 
NANOMETERS 
Noradrenalin 285 325 
p-Hydroxyphenethylamine 285 325 
Adenine 280 375 
Iudole 280 355 
3,4-Dihydroxyphenylacetic Acid 280 330 
3,4-Dibydroxyphenylserine 280 320 
p-Hydroxyphenylacetic Acid 280 310 
Tyramine 275 310 
Tyrosine 275 310 
Vitamin B12 275 305 
Riboflavin 270,370,445 520 
Homovanillic Acid 270 315 
Equilenin 250,290,340 370 
Note: Measurements in mu (millimicrons or nanometers) 
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TABLE IIA-4. NATURALLY OCCURRING PHENOLIC COMPOUNDS
 
FOUND IN BIOLOGICAL MATERIALS (Continued)
 
Th-l-arnino-4 
hydroxyanthraquinone 
Be-1-4-dihydroxy 
anthraquinone 
Be-l-amino-4 
hydroxyanthraquinone 
Al-PBBR 
Ai-AAGR 
Re-morin 
Al-morin 
Zr-flavonol 
A-Creatinine 
B-Dimnethyl-guanidine 
C-Guanido Acetic Acid 
.D-Methy guandine 
E -Aginine 
F-Guandine 
Li-oxine 
B-benzoin 
7-Hydroxyqidnolines 
Hydroxyquinolines 
7-Hydroxycoumanins 
Hydroxycoumanins 
NANOMETERS
 
550-580 
530-570 
530-560 
470,580 
470 
470 
430 
400 
390 
390 
390 
390 
390 
390 
370 
370 
370 
365 
365 
320 
660 
630 
620 
.630 
590 
555-585 
500 
465 
495 
495 
495 
495 
495 
495 
580 
480 
490 
460 
.460 
480 
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TABLE I[A-4. NATURALLY OCCURRING PHENOLIC COMPOUNDS
 
FOUND IN BIOLOGICAL MATERIALS (Continued)
 
0-Hydroxycinnamic (cis) 
(coumarinic acid) 
0-Hydroxycinnamic (trans) 
(coumaric acid) 
4-Pyridioxdc Acid lactone 
8-Naphthol 
p-Hydroxycinnanic 
3-Hydroxyquinolines 
2:6-di (Y-resorcylic) 
3-(10 ug./ml.) hydroxycoumanins 
a-Naphthol 
2-Hydroxyquniolines 
2:5 --di-(gentisic) 
o-Hydroxydiphenyl 
Warfafrn in methanol 
Potasan (in methanol) 
3-Salicylic Acid 
2, 3-Dilydroxy indole 
3, 4,Dibenzpyrene 
8,9
 
p-Hydroxydiphenyl 
Hydroxycoumanins 
4-(5 ug./mL) hydroxycoumanins 
Indoxyl 

2:3-di-(catechuic) 
NANOMETERS
 
365 510
 
365 500
 
360 440-445
 
350 460
 
350 440
 
350 450
 
420-430
 
340 455
 
340 480
 
330 480
 
325 380
 
325 455
 
320 420
 
320 385
 
320 385
 
315 425
 
315 400
 
310,335,390,410 480,510
 
310 410
 
310 390-400
 
310 360-380
 
310 395
 
305 440
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TABLE IIA-4. NATURALLY OCCURRING PHENOLIC COMPOUNDS
 
FOUND IN BIOLOGICAL MATERIALS (Continued) 
1, 12 Benzperyiene 
3:4-di-(protocatechuic) 
Oxindole 
p-Hydroxymandelic 
8,9Benzfluoranthrene 

2-(salicylic acid) 
2:4-di-(B-resorcylic) 
3-Salicylic Acid 
Naphthacene 
1, 2 Benzpyrene in cyclohexane 
Skatole 
Methylanflie 
p-Hydroxyphenylpyruvic 
2:5-Diliydroxy (homogentisic) 
Indoxyl acetate 
Indole acetic acid 
in methanol 
Quinol (1:4) 
p-Cresol 
2:4-Xylenol 
Naphthacenene 
8-Methyl Fluorene 
1-2 Benzanthrene 
NANOMETERS
 
305,375,395 
300 
300 
300 
295,330,385, 

405
 
295 

295 

295 
290,310 
290,330 
290 
290 
290 
290 
285 
285 
285 
285 
285 
280,390,415, 

445 
280,290,365 

280,340 
430 
370 
345 
380 
480,515
 
420 
400
 
350 
480,515 
410 
370 
360 
340-350 
340 
375 
345 
340 
315
 
310
 
480
 
460-480
 
390,410 
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TABLE IA-4. NATURALLY OCCURRING PHENOLIC COMPOUNDS
 
FOUND IN BIOLOGICAL MATERIALS (Continued) 
2-Methyl indole 

Indole 
Aniline 

Aniline 

3:4-Dihydroxy 
(homoprotocatechuic) 
3:4-Dimethoxy 
1-Arternol Bitartrate 
I-Epinephrine Bitartrate 
3:4-Xylenol 
m-Cresol 
4-Hydroxy 

o-Cresol 
2:6 -Xylenol 
3:4-trimethoxy-benzoic 
5-
Catechol (1:2) 
3-Hydroxy-4-methoxy 
(homovanillic) 
Phenol 
2-Hydroxy 
Phenol 
Anisole 
Resorcinol (1:3) 
3:4-Dibenzpyrene 
9,10 

acid 
NANOMETERS
 
280 

280 
280 

280 

280 
280 
280 
280-
280 
280 
275 

275 

275 

270 

270 

270 
270 

270 

270 

270 

265 

255,290,300 

395,415,445
 
355
 
350 
340
 
340
 
330 
325 
320 
320 
310 
305 
315
 
305
 
305
 
375 
325
 
315 
310 
310
 
310
 
3.00
 
315
 
455,485
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TABLE IIA-4. NATURALLY OCCURRING PHENOLIC COMPOUNDS
 
FOUND IN BIOLOGICAL MATERIALS (Continued) 
Dimethylanfline 
Guthione 
Chrysene 

n-Propylsome 
Piperonyl butoxide 
in methanol 
Benzanthrene 
1, 2,Dibenzpyrene 
3,4 

Naphthalene acetamide 
in methanol 
Naphthalene acetic acid 
NANOMETERS 
255 
250,312 
250,300,310 

248,292 

248,292 
245,325,340 
230,285,305 
325,340,375
 
230,286 
230, 282 
Note: Measurements in mu (millimicrons or nanometers) 
370 
380 
360,380
 
326 
320 
385,400 
4403'470 
327 
325 
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5.15 DAY-NIGHT PHOTOGRAPHY 
EXPLANATION OF TECHNOLOGY 
Behavioral studies of the Primate Mission required black and white still and cine mode 
photography of the animal subject during both day and night periods while maintaining the 
day to night lighting intensity ratio at greater than 30:1 in the visible spectrum to maintain 
circadian response. 
Plus X Pan-film was employed which has a dynamic range of only 8:1 with incadescent 
lighting, and therefore required two different exposure settings to obtain both day and 
night photographs if unfiltered incandescent lighting were employed. Because variable 
exposure represented major modification to the camera and to the electronic control 
components, a means was sought to provide high resolution day and night photography 
without such changes. 
The system developed took advantage of the difference in spectral response of the film 
and the primates' eye. Because about one third of the film's response is in the visible 
range and two-thirds in the near infrared, the night light was filtered with a Wratten 70 
(deep red) filter while the day light remained unfiltered. The resu;ting night light had a 
visible energy content 1/30 to 1/125 of that of the day light while maintaining a film­
responsive energy content 1/2 to 1/8 that of the day light, or within the latitude of the film. 
Consequently, a single camera setting could then accommodate both day and night lighting 
conditions.
 
The influence of the white/red day/night lighting system on circadian response was tested 
at the Ames Research Center, using both chickens and primates. Normal circadian 
rhythms were reported. 
UNIQUENESS 
Although state-of-the-art technology was used in this method of black and white day-night 
photography, its application to medicine may provide costs savings where it is desired to 
provide unattended photography for recording visual observations of patients. Where the 
normal method involves changing exposure for different lighting conditions, less expensive 
equipment without automated exposure setting may be employed with the photography/ 
lighting method described. A unique feature of the approach will be the use of a simple 
logic circuit and sensors to automatically control the camera so as to take pictures only 
when patient condition warrants. This will limit and mimimize the number of photographs 
to those of potential clinical interim. 
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END PRODUCTS 
A report shall be supplied detailing the requirements and application of an automated 
camera-lighting system for medical use. Also, the report shall include conceptual designs 
on economical lighting and photography systems for automated time-lapse monitoring of 
intensive care patients, psychiatric patients, or significant subjects in operating rooms. 
RECOMMENDED PROGRAM 
Investigate the potential usefulness of day-night photographic techniques for monitoring 
different types of patients, e.g., psychiatric, pediatric etc., who require continuous or 
intermittent surveillence. This would include application of state of the art time-lapse 
or continuous cinema-photography with closed circuit (CCTV) options. Analyze and define 
camera control techniques based on physiologic parameter status. 
An initial program would call for an applications evaluation to determine the requirements 
of the medical profession for such a system. Based upon the outcome of this study, 
recommendations would be made to design and fabricate a prototype system which would be 
evaluated clinically. 
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5.16 ODOR CONTROLLED WASTE COLLECTION SYSTEM FOR COLOSTOMY AND 
ILEOSTOVY PATIENTS REQUIRING SURGICAL APPLIANCES (FECES COLLECTION) 
INTRODUCTION 
A Primate Feces Collection and Storage Assembly was developed for the Biosatellte Pro­
gram to provide retention of primate feces (liquid and solid) for periods in excess of 30 
days. 
Liquids and solids accumulating during this period were retained by a filter in the container 
wall while permitting gasses to flow through a bacterial filter into a Gas Management Assem­
bly system equipped with a charcoal scrubber. Recirculation of air in this system provided 
continuous removal of primate flatus and odors eminating from waste materials. 
It would be of considerable interest to apply this technology, or modifications thereof, to the 
development of an advanced odor controlled waste collection system suitable for colostomy 
and ileostomy patients. 
STATE OF THE ART TECHNOLOGY 
Radical surgery of the intestinal tract in adults and children frequently requires the termi­
nal end of the colon or ileum to be exteriorized in the abdominal wall. Waste products are 
collected in a plastic or rubber container frequently referred to as "-ostomy or surgical 
appliances". 
The appliance is attached to the "stoma" with a non-irritating gasket and held in 
place with a belt fastened around the patient's waist. Although the gasket is primarily 
intended to minimize friction between the stoma and collection system, it likewise acts as 
a seal to prevent leakage of intestinal secretions capable of irritating the skin and staining 
clothing. 
Filling of the waste collection system is partially dependent on intra-intestinal flow produced 
by successive peristaltic waves, and gravity displacement of air in the appliance. 
Offensive odors, e.g., H2 S, eminating from the feces may leak out at the seal site or diffuse 
through the appliance wall. 
Gas production and the volume of waste products collected daily varies with the physiological 
status of the individual, age, eating habits, as.well as miscellaneous contributory factors. 
For this reason, some patient types may have severe odor problems and require frequent 
emptying and/or replacement of the appliances. Bed ridden geriatric patients, conversely, 
may only require appliance replacement every 7-10 days, but will still have annoying mode­
rate to severe odor associated problems. Chemical masking agents have been variously 
used, but unfortunately only provide a temporary relief. In many instances, these may be 
highly perfumed and not aesthetically acceptable to the patient or his associates. 
To date waste collection systems are not available that provide effective control of odor pro­
ducing gases and/or constituents of feces. 
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A. 	 Locus of stoma in colostomy patient. B. Cross section of abdominal wall, 
colon, and stoma. 
Figure IIA-20. Exteriorized Colon with Exposed Stoma in Colostomy Patient 
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Figure IIA-21. Conventional "-Ostomy Appliance" Attached to Stoma of Colostomy Patient, 
Gas and Odors Escape from Appliance at Site of Attachment (Stomay-to Body 
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(1) 	 Water (H20)in feces leaches antimicrobial agent, e.g., sodium dibutyldithiocarbamate(A), from inner wall of appliance and fills and/or inhibits the growth of gas (odor) pro­
ducing microflora. 
(2) 	 This is intended to minimize or eliminate 'back pressure" of gases and their subsequent 
escape into the surrounding environment. 
Figure ItA-22. Leaching of Water Soluble Antimicrobial Agent from Internal 
Wall of Appliance and D9strbtion of Gas Producing Microflora 
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UNIQUE ADVANCED TECHNOLOGY 
An advanced waste collection system for colostomy and ileostomy patients would provide 
the following features: 
1) Disposable appliances 
a) adult sizes 
b) children sizes 
2) Gas scrubber options 
a) Self contained scrubber 
b) Reuseable cartridge type 
c) Gas management assembly (self contained scrubber): line or battery 
operated 
3) Appliance materials 
a) Laminated plastic (gas impermeable) exterior 
b) Antimicrobial containing lining 
c) gas permeable lining 
4) Silastic seal 
5) Non-toxic 
6) Adjustable belt 
The proposed system would use a new concept in odor control for this type of product: 
(a) scrubbing of odor producing flatus and gases by means of (1) a self-contained activated 
carbon scrubber, (2) replaceable, cartridge-type scrubber, (3) isolated gas manage­
ment assembly (GMA) suitable for operation from a nickle-cadmium battery. (b) retard 
growth of gas producing microflora in the feces by incorporating a water soluble anti­
microbial agent in the lining of the gas-permeable lining. 
In addition, the appliance would be equipped with a non-toxic, non-irritating silastic 
seal based upon the~size of the patient's stoma; an adjustable belt to hold the appliance 
securely to the body; and a polyethyiene bag and tie for disposal purposes, 
11-88 
\112S
 
SELF CONTAINED 2 GAS FROM PATIENT'S 
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-- H S COLON 
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Figure IIA-23. Conceptual Design of a Odor Control System for a Disposable 
"Ostomy" Appliance. Cross Section to Show Gas Scrubber in Operation 
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Figure IIA-24. Cenceptual Design of a Odor Control System for a Reaseable "-Ostomy" Appliance.
Cross Section to Show Gas Scrubber in Operation and Replaceable Charcoal Cartridge 
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Figure IA-25. Conceptual Design of a Odor Control System for a Disposable "-Ostomy' 
Appliance. Front View to Show Simple Charcoal Unit with Gas Baffles. Charcoal is 
Sealed in pouch at top of unit; Baffle prevents openings in scrubber from being 
Obstructed by Particulate Matter and/or Moisture. 
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Figure IHA-26. Conceptual Design of a Odor Control System for a Disposable "-Ostomy"Appliance. In Comparison to Design Imustrated in Figure 6 Pouch for Absorbent is 
Continuous and Not Limited to the Top of the Unit. 
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Concept #1. Disposable waste collection Concept #2. Re-useable waste collection 
system (A) with self contained odor con- system (A) with disposable (cartridge­
trol sub-system, See Figs. 4,6,7, equipped type) charcoal scrubber (B). 
with a bacterial filter vent (B). 
Concept #3. Disposable waste collection 
system in sita (A) connected with flexible 
tubing (C) to battery operated Gas 
Management Assembly (B). 
Figure IIA-27. Odor Controlled Waste Collection System: Conceptual Design 
of Gas Management Assembly 
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SUGGESTIONS FOR PRODUCING AN END PRODUCT 
1) Optinize design of gas scrubbing sub-systems and breadboard 
2) Optimize materials for appliance fabrication 
3) Optimize appliance and seal design 
4) Breadboard system and test 
5) Prototype fabrication
 
6) 6-9 month clinical trials
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SCHEDULE PLANNING SHEET HUMAN WASTE COLLECTION 
RESP.O N PROG WORK IEI TASKo.PEPARED Y RM. EXT. DATE ISSUED TITLE OF SEGMENT OF WORK 
-PURPOSE VOW ESTIMAT APPROVALS 1 REFERENCES - P.P.I.NO. REV. OTHER 
ITEM NO. DESCRIPTION OF WORK ITEM ELAPSED TIME SCHEDULE 
(INDICATE YEARS/ QUARTERS/AL4ON-THA AS APPLICABLE ) 
1 3 5 7--9 11 13 15 17 19 21 23 25 27 29- 3133 35 37 39 41 43 45 47 49 
1 Preliminary Field Survey (Med. Cente p k I 
2 Optimize desig of gas scrubbing 
sub-svstem 
3 Breadboard Las scrubbin system : :6 
4 Test breadboard gs scrubber 
5 Optimize appliance materials 
6 Test appliance materials 116­
7 Breadhoard total system 
8 Advanced Field Survey 
9 Prototype fabrication 
10 Clinical trials 
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5.17 	 DEVELOPMENT OF AN AUTOMATED URINE COLLECTION AND MEASUREMENT 
SYSTEM 
1.0 TECHNOLOGY DESCRIPTION 
Urine collection and measurement was accomplished on the Biosatellite Primate Mission 
to provide urine for analysis (See XIV) and to maintain the cabin habitable for the primate. 
This task was accomplished with a 100 milliliter capacity collector, a peristaltic pump 
and a metering valve (10 cc), see Biosatellite Technology Summary. It is proposed that 
a prototype system, based on this technology, be developed and clinically demonstrated. 
2.0 RECOMMENDED PROGRAM 
Early 	verification of the applicability of the biosatellite type system may be demonstrated 
-utilizing available biosatellite hardware. Conversion of the equipment-design to satisfy 
clinical application and remove aerospace constraints would be followed by fabrication, 
installation and checkout of a prototype operational unit in a receptive hospital (approxi­
mately four months after contractual authority to proceed). Technical liaison, data 
evaluation and reporting in support of the hospital staff would be accomplished over a 
three month period. 
Further technical, scheduling, and costing details are in the CCN to Contract AASW 2073-
Proposal F32012. 
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1. 0 ORGANIZATION 
1.1 CORPORATE ORGANIZATION 
The General Electric Company is organized into eleven product groups reporting to the 
Corporate Executive Officers. Each group is composed of a number of divisions which 
are charged with the responsibility of fulfilling their respective business objectives and 
obligations. The Patient Monitor System Prototype Implementation and selected R&D 
Tasks will be performed within the Re-entry and Environment Systems Division (RESD) of 
the Aerospace Group (see Figure IB-i). Mr. Mark Morton, is the Aerospace Group 
Executive and a GE Vice President. The Re-entry and Environmental Systems Division is 
under the leadership of Mr. Otto Klima, Jr., Vice President and General Manager. 
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Figure JIB-I. General Electric Corporate Organization 
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1,2 DIVISION ORGANIZATION 
In the program management/functional organization structure of GE-RFSD, as illustrated 
in Figure 13B-2, a number of program management sections have been established: 
Space Re-entry Systems, Strategic Systems, Ocean Systems, Urban Systems, and Opera­
tional Systems. These sections are supported by the functional organizations of Research 
and Engineering, and Operations and Evaluation (which includes Systems Test and Opera­
tions, Manufacturing, Quality Assurance, Materiel and Facilities), as well as the service 
organizations such as Finance, Legal, and Contracts. 
Space re-entry systems programs, including Bioscience Programs, are performed under 
the management of Mr. Walter D. Smith, General Manager, Space Re-entry Systems Pro­
grams. Mr. R.F. Welsch, Manager of Bioscience Programs has cognizance of all Bio-
Space and Medical activities for the Division. 
11-102 
0. XMIA 
VICE PRESIDENT 
AND 
GENERAL MANAGER 
RE-ENTRY AND 
ENVItONMENTAL 
SYSTEMS DIVISION 
I I I I 
FIANC AND 
CONTR;ACT 
MANAGEMRENTFMANAGER 
GEEAWAAE 
MANAGEMENTRESEAMCIIAND 
ENIERNVLAIN 
ENRLMNGRI. 
OPERATIONSAND 
D. SMITH 
GENERAL MANAGER 
SPACE RE-ENTRY 
SYSTE MPOGRAMS 
GERAMNGR 
STRATEGIC 
SSESPORM 
GNELMNGR 
OCEANSYSTEMS 
RGASPORM 
GNRLMNGE 
URBANSYSTEMS 
SI I I 
MILITARY 
SPACEPROGRAMIS 
VIIGNG 
SUPPCRTPROGRIAM 
SPACE 
TRANSPORTATIOAPROGRAMS 
MANAGERV 
BIOSCIENCE 
PROGRAMS 
SYSTEMTS REQIRE ME NTS PLANINGCOTAS 
Figure IIB-2. General Electric Re-entry and Environmental 
Systems Division Organizations 
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2. 0 MANAGEMENT 
The proposed tasks will be under the direction of Mr. Welsch with support of the contribu­
tors to the PMS study contract effort. Mr. W.A. Buck, as Project Manager will focus all 
tasks associated with this effort. 
The PMS task will be organized to provide single point control of three key functional 
activities: 
* Hardware Design 
* Software Design 
* Manufacture, Assembly and Test 
The R&D tasks will be lead by individuals with proven technical skill and experience related 
directly to the specified task as well as managerial capability. R&D task support teams 
will be assigned on the basis of capabilities and experience in the disciplines and technologi­
cal skills. 
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TABLE ]IB-I. KEY PROGRAM PERSONNEL 
Percent Years Experience 
Name and Function Education and Related Experience of Time Total GE 
R.F. WE LSCH BSME - University of Wisconsin 22 20 
Bioscience Programs * Program Manager, MK-3C Program - An airborne 
Manager radar map-matching system using terminal gui­
dance equipment in re-entry vehicles. 
* 	 Program Manager, Terminal Radiation Program -
An optical tracking system for re-entry measure­
ments. 
* 	 Program Manager, Maneuvering Ballistic Re-entry 
Vehicle Program (MBRV). 
* 	 Program Manager - Overall responsibility for 
management of NASA's Biosatellite series of 
orbital-recoverable spacecraft. 
W.A. BUCK 	 BSME, University of Rochester 
Project Manager * Supervising Engineer - Apollo Program - digital 80 11 7 
data systems design for automatic spacecraft 
acceptance checkout equipment (ACE). Operations 
Engineering of the ACE system and related space­
craft checkout systems. 
* 	 Manager - Central Ground Station - established and 
developed centralized computer controlled data 
acquisition system for support of systems test. 
* 	 Manager - Minuteman Im R/S and P/A systems test, 
performance of systems development, flight proof 
qualification and acceptance tests of R/S and P/A 
systems. 
0 
TABLE IIB-I. KEY PROGRAM PERSONNEL (Continued) 
Percent Years Experience 
Name and Function Education and Related Experience of Time Total GE 
DR. J.J. SHULL BS, MS, and PhD - Pennsylvania State Univeristy 	 25 19 5 
Biologic Consultant 0 	 Manager, Biological, and Medical Services Laboratory -
Responsible for studies of preservation and analysis of 
biological materials, cardiovascular research, and 
development of life support techniques for spacecraft. 
* 	 Contributed substantially in the area of sterilization and 
microbial control research and development and water 
and waste water treatment and monitoring. 
* 	 Experiments Consultant for Biosatellite - Responsible 
for interface between experimenters and spacecraft 
design personnel. 
DR. D. EKBERG BS - University of Illinois (Chemistry) MS - University 25 13 11 
R&D Tasks of Chicago (Physiology) PhD - University of Illinois 
(Physiology) 
* 	 Senior Aeromedical Engineer, Martin Company -
Aviation Physiology. 
* 	 Postdoctoral Fellow, U.S. Public Health Service -
Research in Temperature adaptation. 
* 	 Physiologist, General Electric Co. - Manned Space 
Vehicle Studies, BIOS I, research involving the bio­
logical effects of very low magnetic fields, bio­
rhythms, temperature adaptation, atmosphere 
selection; amoeba experimenter on Biosatellite I. 
* 	 Adjunct Professor, Environmental Engineering, 
Drexel University. 
* 	 Manager, Biosciences Operation; Space Systems. 
TABLE 1I-i. KEY PROGRAM PERSONNEL (Continued) 
Percent Years Experience 
Name and Function Education and Related Experience of Time Total GE 
DR. N. KUCHAR BS, MS, and PhD - Case Institute of Technology 25 3 3 
R&D Tasks - Bic Fluid * Group Leader, Bjo Fluid Mechanics - Concerned 
Mechanics Manager with research in the area of mathematical modeling 
of fluid dynamics, solid mechanics and transport 
phenomena in biological systems. Areas of re­
search include modeling of the pulmonary circula­
tion, an investigation of flow and mass transfer in 
blood oxygenators, a study of the onset of turbu­
lence in blood flowing in artificial pumping devices, 
and investigation of the effects of weightlessness 
and high acceleration on the distribution of blood 
in the human body. 
B.C. BURGESS BSEE, University of Southern California 90 15 10 
PMS Software Systems ME Administration, Syracuse University 
* Urban System Engineering - data systems manage­
ment, programming and data processing. 
* Systems engineering of electronic and digital systems 
for air weapon control and spacecraft/launch vehicle 
pre -flight checkout. 
* Manager - Data Processing, Apollo/Saturn Space 
Programs. 
S.G. KRITZSTEIN BSEE, MSEE, University of Pennsylvania 90 11 11 
PMS System Engineer * SystemDesign Consultant to Telemed Program, 
University of Missouri. 
* System Design Consultant for Arizona Heart Institute 
Facility. 
H 0 Primary system design for manned simulator on the 
Manned Orbital Lab Program. 
TABLE HB-i. KEY PROGRAM PERSONNEL (Continued) 
Percent Years Experience 
Name and Function Education and Related Experience of Time Total GE 
M.A. MALO BSEE, University of Miami 80 12 5 
PMS Product 0 Product Development Engineer, Multiphase Medical 
Development Engineer Data Acquisition Unit. 
* 	 Product Development Engineer, Ocean Programs. 
* 	 Project Test Engineer, Biosatellite. 
" 	 Group Leader, Thor/Delta Space Vehicle Test and 
Launch, Douglas Aircraft Co. 
J.A. GANNON BEE, Catholic University of America 75 13 4 
PMS Project Test MS Electrical Engineering, University of Connecticut 
Engineer e Biosateflite Project - primate mission - primate/ 
spacecraft interface engineer covering life support, 
behavioral testing and physiological monitoring sys­
tem. 
* 	 Project Engineer on Lankenan Hospital Electrocardio­
gram Program. 
* 	 Design/development and test of electronic and 
electromechanical analog computer systems. 
R.B. LANDIS Aero Engineer, Pennsylvania State University, and 50 27 8 
Project Integration Oklahoma A&M 
* 	 Chief Project Engineer - Prewitt Aircraft Corp., 
Clifton Heights, Pa Design/development of bonded 
metal rotor blades. 
* 	 Development Engineer - Skybolt Project, GE-RESD. 
Subsystem requirements, design and integration. 
* 	 Program Requirements - Biosatellite Project - GE-
RESD. Technical requirements, interface control, 
documentation, technical integration. 
TABLE JIB-1. KEY PROGRAM PERSONNEL (Continued) 
Percent Years Experience 
Name and Function Education and Related Experience of Time Total GE 
M.K. WOLFSON BSE (ME & AeE), University of Michigan. Registered 25 24 24 
Project Control Professional Engineer - Massachusetts 
* 	 206 Program: Project Engineering Manager in pro­
gram office responsible for system and subsystem 
integration and planning, and control of all in-house 
activities in support of vehicle delivery. 
* 	 MBRV: Project Manager responsible for planning, 
scheduling, and control of total program with 
special assignments as Vehicle Manager to assure 
on-time delivery. 
* 	 Biosatellite: Program Manager responsible for 
planning, scheduling, and control of detailed pro­
gram activities, customer interfaces for scheduling, 
financial and business matters, and proposals. 
T. P. FROST BS Electrical Engineering - (cum laude) Princeton 75 20 16 
Computer System University 
Engineer * Information systems and digital computer applica­
tions engineer. 
* 	 Biosatellite Project - design/development of com­
puter systems used in systems testing of spacecraft. 
* 	 Automated real-time systems testing for dynamic 
environment tests of all types of aerospace equip­
ment. 
TABLE EB-i. KEY PROGRAM PERSONNEL (Continued) 
Name and Function Education and Related Experience 
Percent 
of Time 
Years Experience 
Total GE 
DR. KARL SITTEL Physics, Physical Chemistry, Biophysics 75 31 4 
Consultant, Biomedical 
Technology Projects 
University and Max Planck Institute for Biophysics, 
Frankfurt am Main, German, PhD 1940 
* Staff Consultant with GE/ESL - Physiological systems 
modeling: cardiovascular system and myocardium 
biomedical technology. 
* RCA - System physics, staff member and group 
leader. 
* Franklin Institute - Senior Staff Physicist; bio­
acoustics, viscoelasticity, instrumentation. 
* Jefferson Medical College - Consultant in Bio­
acoustics. 
* US Navy - Aeromedical Equipment Laboratory, 
Leader of Bioinstrumentation Laboratory, electri­
cal impedance of biological materials, bioaccustics. 
* German Marine Observatory - Director of Aerologi­
cal Instrumentation Laboratory 
DR. W. EDWIN SAUER BS Chemistry, Ursinus College, 1957 50 13 7 
Biochemical Engineer MS Physics, University of Pennsylvania, 1964 
PhD Materials Engineering, Drexel Institute of Techno­
logy, 1969 
* Biochemical Engineer - GE Environmental Sciences 
Laboratory. 
* Materials Engineering Department, Drexel Institute of 
Technology - Research Associate, transition metal 
solutes and the electronic and magnetic structure of 
iron-base alloys.
* Space Sciences Laboratory, GE - Materials Physicist, 
thin film processes, sputtering process for metallizing 
co 
fivers, laser evaporation process for congruent alloydeposition. 
Name and Function 
DR. W. EDWIN SAUER 
(Continued) 
DR. MARCEL MARTIN 
Cardiac Programs 
Development 
DR. E. LANGBERG 
Manager, Cardiac 
Monitoring Systems 
RESD 
A. BRYCE 
Bio-Chemical 
Systems Engineer 
TABLE KB-io KEY PROGRAM PERSONNEL (Continued) 
Percent Years Experience
Education and Related Experience 	 of Time Total GE 
0 	 Semiconductor Division, Philco-Ford Corp. -
Chemist, electro-chemical processes for transistor 
fabrication; Department Supervisor, directed electri­
cal testing of transistors. 
PhD (Physics) - Institute of Optics, Paris, France, 1934 50 36 14 
0 Research and Design - Microscopes & Microscopy, 
American Optic Co. 
* 	 Digital Computer Design, Jacob Instruments 
* 	 Digital Computer Design and Applications, Burroughs 
* 	 Manager, Scientific Data Processing and Handling 
o 	 Consulting Physicist - Cardiac Program Development 
BSEE, University of Pennsylvania, 1953 50 14 1 
PhD Electrical Engineering - (Physics) 1956, 
Princeton University 
0 Industrial, Scientific and Medical Instrumentation 
* 	 Research Staff, New York Medical College 
* 	 Consultant, MIT Lincoln Lab. 
* 	 Consulting Engineer, Bio-science Program RESD 
BA (Biology) - Temple University 30 14 10 
a Pharmaceutical screening, BMR measurements, 
Bioassay procedures - Smith, Kline & French 
* 	 Research and development of closed cycle ecologi­
cal systems and waste recycling. 
* 	 Biological and biochemical methods development 
for clinical testing and bioassay procedures. 
TABLE IIB-I. KEY PROGRAM PERSONNEL (Continued) 
Percent Years Experience 
Name and Function Education and Related Experience of Time Total GE 
DR. V. KLEMAS BS, Electrical Engineering, M.I.T. 30 10 10 
Manager MS, Electrical Engineering & Physics, M.1I.T. 
Optical Physics PhD, Optical Physics, Technical University Braunschweig 
* Manager of Optical Physics and Pollution Sensing Pro­
jects at GE's Environmental Sciences Laboratory; 
remote sensing of environment and detection of man­
made targets, water and air pollution monitors, re­
mote sensing, multispectral imaging, photoimaging 
studies, new optical modulation techniques. 
* Dr. Kiemas is currently a lecturer on Laser Theory 
and Applications, Pollution Sensing and Remote 
Sensing of Environment at the Penn State Graduate 
Center. 
H 
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4. 0 TASK STATEMENTS 
The following tasks statements broadly define the proposed activity for Patenit Monitor 
System implementation and R&D Task Performance. 
4.1 PATIENT MONITOR SYSTEM IMPLEMENTATION 
* 	 Provide design and development costs (up to *) 
* 	 Develop and issue program and management plans (including detail work state­
ments) ­
* 	 Finalize the PMS system specification 
* 	 Analyze and trade off design solutions; issue design specification 
* 	 Accomplish prototype hardware and software design and development; issue 
prototype drawings 
* • Provide a manufacturing plan and schedule, an integrated test plan and schedule, 
and estimated costs 
* 	 Procure material and hardware; initiate fabrication cycle 
* 	 Issue prototype test and evaluation procedures 
* 	 Complete fabrication and initiate factory test and development tasks 
* 	 Issue operations plan, operational procedures, evaluation criteria and maintenance 
notes 
* Box, pack and ship
 
a Install and verify equipment operability
 
* 	 Integrate hospital supplied equipment, procedures and personnel; provide opera­
tional training 
* 	 Support clinical evaluation of system 
* 	 Provide routine maintenance and repair 
* 	 Provide periodic task reviews and reports 
* 	 Provide a final report and recommendations 
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4.2 R&D TASKS 
* 	 Provide expanded descriptions of task elements as delineated in the task summary 
sheets, Section H A-5. 0 
* 	 Provide task costs (excluding hardware costs since hardware is not yet defined) 
* 	 Proceed with authorized tasks as delineated 
o 	 Where applicable provide hardware recommendations, conceptual designs and 
estimated hardware costs 
* 	 Provide periodic task review and letter reports 
* 	 Provide final report and recommendations 
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R&D TASKS WITH PATIENT MONITORING SYSTEM IMPLEMENTATION
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5.0 	 PROJECTED INTEGRATED SCHEDULE OF R&D TASKS WITH PATIENT MONITOR-
ING SYSTEM IMPLEIVIENTATION 
A recommended integrated schedule of tasks is given in Figure IIB-4. This schedule 
coordinates R&D task activities that are interactive with PM System Implementation phases 
and with other R&D tasks. Although each task may be accomplished and effective indepen­
dently, significantly increased value or application of value will be realized by phasing 
and coordinating the results of the tasks as shown. 
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MONTHS FROM CONTRACT INITIATION 
1971 -
1 2 3 4 5 0 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 
PMS IMPLEMENTATION 
- DES[GN/DEVEIOPMENT 
- MANUFACTUIUNG/TEST 
-
- INSTALLATION, DEBUGGING &VALIDATION 
- CLINICAL EVALUATION & OPERATIONS 
TASK 5.1 - COMBINED PM SYSTEMS 
TASK 5.2 - MED. EQUIP. PARAM. EVAL. -
TASK 5.3 PM TELEMETRY MONITOR 
TASK 5.4 - COMPUTER ANALYSIS TECH. ---
TASK 5.5 - RESPIRATORY ANALYSIS 
TASK S.6 - AMPS &SIG. COND. STND--
TASK 5.7 - NARROW BAND VIDEO - - --
TASK 5.8 - NON INVASIVE TECHNIQUE 
TASK 5.9 - SENSOR CONNECTOR STNDS. 
TASK 5.10 - IV FLUID DISPENSING 
TASK5.11 - SENSORMATERIALSTNDS. h 
TASK 5.12 - STANDARD MEASUREMENTS I A. -
TASK S.13 - AUTO URINE ANALYSIS 
TASK5.14 - PHENOL ANALYSIS 
TASKS.15 - DAY/NUT PHOTOGRAPHY 
TASK 5.16 - WASTE COLLECTION -
TASKS.17 - URIN COLLECTION (SEPARATE CUM 
flgure IIB-4. Recommended Integrated Schedule 
6.0 BUDGETARY COST ESTnVIATES 
11-122
 
6.0 BUDGETARY COST ESTIMATES 
6.1 INTRODUCTION 
Budgetary cost estimates were developed for implementation of the patient monitoring sys­
tem and are delineated in paragraph 6.2. Order of magnitude cost data are provided for 
a total prototpe systems and for portions thereof. 
Additionally, in paragraph 6.3, preliminary cost data are provided for each of the re­
search and development tasks proposed in Section HA, paragraph 5.0. 
6.2 PATIENT MONITOR SYSTEM 
6.2.1 Assumptions 
Certain assumptions have been made in costing the patient monitoring system. These 
assumptions were made to reflect the availability of already developed medical, aerospace, 
and commercial technology, equipment, and facilities. As found from the survey of the 
four host hospitals, from the literature searches, from endeavors by the team members 
in other medical areas, and from aerospace experience it is possible to assemble advan­
tages that can save time, money, and strengthen the communications between the medical 
and engineering personnel who will perform this work. 
In configuring the systems for the purposes of program planning, scheduling, and budgetary 
cost estimates; the following assumptions were made: 
a. The same basic computer would be used for Modules I, 11, TEE and IV. As require­
ments (unique to the applications of each module) change, the basic computer 
configuration would change in such things as core size, peripherals, etc. 
b. The larger "host" computer of Module 11, used to augment the basic minicomputer, 
is not included in the costing. The relatively small amount of time required of the 
more powerful machine was considered to be made available by the hospital. 
c. The "OPTIONAL" equipment as listed in the Final Report in the Section VI matrix 
DATA PROCESSING SUB-SYSTEM are not included in the costing. 
d. Equipment usually supplied by the hospital that would be employed by the Patient 
Monitoring System was not costed. These include such items as EKG machines, 
blood and urine analyzer, catheters, sensors, etc. 
e. Consultantlservices, as required, would be supplied through the contracting agency0 
f. In acceptance of the computer it was assumed that that function would be performed 
in the manufacturer's facility. 
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g. 	 The patient monitoring program in the form of a card deck copy, printout listing, 
and/or a magnetic tape copy in machine level language and/or assembly language 
would be available on request to the contractor. These programs would not have 
descriptive documentation. 
h. 	Each of the modules described will handle four (4) patients each. The full system 
will handle four (4) patients per module or potentially sixteen (16) patients total. 
i. In defining and costing the systems the following types of equipment configurations 
were included: 
Modules I, I,Iff. 	IV, and' Full System* 
Signal Conditioner (4)
 
Multiplexer - Analog to Digital Converters
 
Analog to Digital Interface
 
Time Code Generators
 
Time Code Interface
 
Data Entry and Logical Controls
 
Minicomputer
 
Paper Tape Reader/Punch
 
Remote Input/Output Interface
 
Nursels Station Input/Output
 
Cables
 
Equipment Cabinet
 
Power Supplies
 
Nurse's Station 
Data Entry 
Al arm System
 
Analog Recorders
 
Digital Display
 
* NOTE: The 'TullSystem" includes the functions performed by Modules I, 11, I1, and IV 
but it does not include a Nurse's Station. 
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Alpha-numeric/Graphic CRT Device 
Command and Control Logic 
Switching interface 
Hardcopy Printer 
Analog CRT 
Console Enclosure 
Analog Amplifier Assembly 
System Switching and Data Bus 
j. 	 The prototype system's minicomputer will have customer furnished peripheral equip­
ment to be used in the development and checkout stages of the systems. This would 
include magnetic tape, disc, card reader/punch, typewriter, printer equipment, and 
adequately large core memory appropriate for developmental activities. 
k. 	 Development or demonstration of the Patient Monitoring System's capability for 
remote sites is not in scope. 
6.2.2 Cost and Pricing Information 
Classification of Direct Labor 
The direct labor effort to perform each task/subtask of this proposal has been estimated 
in units of manhours by engineering, manufacturing, quality control, and project personnel. 
These manhour estimates have been evaluated based upon past experience to assure their 
reasonableness; e. g., the engineering direct labor hours for this program were developed 
by the engineering section planning personnel through analysis of the work statement 
requirements. 
The labor rates used in this estimate come from the latest table of Labor Estimating Rates. 
These approved rates include a factor representing a share of each employee t s vacation 
and holiday time, as well as an increment factor for salary increases. 
Direct Material 
The following is a brief description of the types of direct materials used in the costing of 
this estimate, and the basis for arriving at the estimated costs for these materials. 
Material prices are determined in one of three ways: 
(a) 	 They are priced from vendor quotations 
(b) 	 They are priced from recent purchases of similar items. 
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(c) They are priced from engineering estimates for unique or specially designed items 
for which we are unable to obtain vendors t quotes because of design uncertainties. 
Purchase Orders 
Where the functional operations determined that the required items are identical or similar 
to items previously purchased the latest purchase prices for these items were used. 
Other GE Departments 
Work orders and intra-company purchase orders placed with other GE Departments are 
treated as direct material for cost computation purposes. 
Catalog Items 
Prices are based on vendor catalog prices. 
Travel and Living 
Travel and living expenses are charged to burden accounts and are liquidated through the 
application of negotiated burden rates. 
Reports 
This amount represents the estimated cost of publishing reports, exclusive of the research, 
development, and technical writing; it includes editing, illustrating, and typing effort. 
Burden Rates 
Engineering Overhead Expense (EOE) 
Engineering overhead expense includes operating costs that are not considered direct con­
are salaries of supervisory and clerical personnel, depreciation,tract charges. Examples 
travel and living expenses, maintenance, and indirect materials. The estimated EOE rate 
included in the proposal is based upon historical data plus projected future expenses. Allo­
cation of EOE is based on the applied labor costs charged to contracts. 
General and Administrative Expense (G&A) 
This represents the cost of overall administration of the department for the functions of 
Total G&A expensesContract Administration, Finance, Legal, and Employee Relations. 

are allocated to contracts on the basis of total cost, excluding G&A. The estimated G&A
 
rates used in the proposal are based upon historical data plus projected future exblenses.
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6.2.3 Patient Monitoring System Budgetary Cost Estimates 
1. 	 The costs in the table below are related to only one of many different combinations 
and permutations of the four patient monitoring modules. This data represents a 
progression from one basic four patient module, through additions of other modular 
functions to that basic module. That is, Module I would be constructed first. 
Then, to that basic Module II, would be added the required elements of Module I, 
Module Ill, and/or Module IV. The initial development costs include non-recurring 
costs associated with the first system only. The costs associated with pro­
visioning subsequent identical modules are estimated to be less than 40 percent 
of the initial costs. 
Patient Monitoring System ROM Costs 
Initial ModulesModules labor material total 
II $498.7K $112.9K $591.6K 
add I 117.6K 56.8K 174.4K 
add lII 306.6K 64.3K 370.9K 
add IV 336.9K 64.3K 401.2K 
2. 	 Another method of producing the four modules is described below. These figures 
represent that which would be required to build modules I, II, I1, and TV all at 
once. Again, additional systems would cost on the order of 60 percent less than 
the initial prototype system. 
Modules I II, 111, and IV ROM Costs 
Initial System 
labor material total 
$847.1K $232.8K" $1,079.9K 
3. 	 The modules described in 1 and 2 above do not include a nurse's station. The 
cost for producing the first nurse's station is as follows: 
Nurse's Station ROM Costs 
Initial Station 
labor material total 
$145.7K $130.9K $276.6K 
Nurse's stations are estimated to cost approximately 30 percent less for produc­
tion versions of the developed prototype. 
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6.3 RESEARCH AND DEVELOPMENT TASKS 
6.3.1 Assumptions 
Budgetary costing has been developed for purposes of assessing the magnitude of each 
proposed R&DItask. In assembling these cost estimates, the following assumptions were 
made: 
a. Consultant services required would be supplied through and funded by the Custo­
mer. These services include those of the advisory committee and those individuals 
responsible for cardiac computer programs. 
b. All hardware required for evaluation and/or modification of "existing methods" 
shall be supplied at no cost to GE-RESD. 
c. All software required for analysis, 
by the Customer. 
evaluation and/or modification shall be supplied 
d. No production costing is included since hardware definition is dependent upon 
early task effort defined herein. 
e. All hardware received on loan from or through the Customer shall have configura­
tion documentation maintained. No irreversible modifications shall be made. 
f. 	 All "on loan" hardware shall be returned to the Customer within 30 days of task 
completion. 
6.3.2 Cost and Pricing Information
 
Refer to paragraph 6.2.2 for cost and pricing information.
 
6.3.3 Budgetary Cost Estimates
 
Budgetary cost estimates for each recommended R&D task are tabulated in the table on 
the following page. 
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TABLE ]IB-2. R&D TASK BUDGETARY COST ESTIMATES
 
Task No. Task Title 
5.1 Combined PM Systems Software 
5.2 Existing Medical Equipment Evaluation 
5.3 PM Via Telemetry 
5.4 Computer Analysis Techniques 
5.5 Respiratory Analysis 
5.6 Amplifier & Signal Conditioner Spec. 
5.7 Narrow Band Video Systems 
5.8 Non-Invasive Techniques 
5.9 Sensor Connectors 
5.10 IV Fluid Dispensing 
5.11 Sensor Materials 
5.12 Standard Measurement Spec. 
5.13 Automated Urine Analysis 
5.14 Advanced Phenol Analysis 
5.15 Day/Night Photography Applications 
5.16 Human Waste Collection 
Labor 
Costs 
$203.5K 
52.OK 
46.2K 
288.4K 
66. OK 
46.2K 
44. OK 
46.8K 
90.0K 
36.7K 
45.9K 
40. OK 
19.6K 
20.4K 
22,7K 
128.2K 
Material 

Costs 

-
-
$ 3.6K 
-
5.7K 
-
5.3K 
1. 2K 
2.3K 
0.8K 
7.3K 
5.4K 
3,6K 
2.4K 
31.5K 
Total 
Costs 
$203.5K 
52.OK 
49.8K 
288.4K 
71.7K 
46.2K 
44. OK 
52. 1K 
91.2K 
39.OK 
46.7K 
47.3K 
22, OK 
24. OK 
25, 1K 
159.7K 
Relative
 
Time Span
 
14.5 Mo. 
12.0 Mo. 
9.5 Mo. 
24. 0 Mo. 
8.0 Mo. 
6.0 Mo. 
6.0 Mo. 
8.5 Mo. 
7.0 Mo. 
To Hardware 
Evaluation, 
10.0 Mo. Total 
8.0 Mo, 
8.0 Mo. 
6.0 Mo. 
3.0 Mo, 
3.5 Mo. 
6.0 Mo. 
6,0 Mo. 
Urine Collection & Measurement (Submitted via Separate CCN) 
_ __ __ _ _ _ _ _ _ _ _ _I _ __ _ 
5.17 
7.0 PLACE OF PERFORMANCE
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7.0 PLACE OF PERFORMANCE 
.The tasks previously defined will be accomplished at Division Headquarters of GE-Re-entry 
and Environmental Systems Division located at 3198 Chestnut Street, Philadelphia, Penn­
sylvania except as noted herein. 
Exceptions include specialized elements of research and development tasks which are more 
suitably accomplished in specific technology oriented laboratories at nearby suburban 
facilities of the Division. These facilities are located in the Space Technology Center at 
Valley Forge and the Cabot, Cabot and Forbes Industrial Park in King of Prussia. 
Additionally, the installation, validation and operational evaluation of PMS equipment pro­
vided by GE-RESD will be accomplished at a medical center designated by the customer.
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III. RE LATED EXPERIENCE 
II A. CORPORATE 
The General Electric Company makes and sells products that axe: 
- used in construction of medical facilities 
- used in hospitals for non-medical purposes 
- components supplied to producers of medical equipment 
(including internal GE elements) 
- health products sold directly to the general public 
- software and services for the medical profession; including computer time 
sharing 
- plastics and other materials used in prosthetics 
- communications products 
- medical x-ray and related products 
Current medical product areas include equipment supplied to professional medical specia­
lists; specifically, radiologists, thoracic surgeons and cardiologists. 
This equipment includes: 
- an extensive array of medical monitoring instruments produced by the Medical 
Systems Division at Milwaukee 
- operating room monitors produced by Canadian GE 
- intravenous flow regulators developed by the Heavy Military Electronics Division 
- Nuclear Eye Monitor, a radioisotope scanner marketed by Space Technology 
Products 
- Cardio-Alert monitors - an ECG telemetry system for emergency vehicles 
marketed by the GE Mobile Radio Department and Canberra Industries 
In summary, diverse capability, experience and beneficial products have been and are 
being developed within the GE Corporate complex. Direct and supporting activities extend 
from the broadly applied Research and Development Center and the Electronics Laboratory 
to the product oriented divisions and departments including the Re-entry and Environmental 
Systems Division in Philadelphia. 
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1.0 RE-ENTRY AND ENVIRONMENTAL SYSTEMS DIVISION,
 
GENERAL ELECTRIC COMPANY
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1.0 	 RE-ENTRY AND ENVIRONMENTAL SYSTEMS DIVISIONGENERAL ELECTRIC
 
COMPANY
 
The Re-entry and Environmental Systems Division of the General Electric Company has 
been actively engaged in research, development and product oriented activities in the bio­
science area for nearly a decade. Bioscience related skills and experience were exten­
sively increased during performance of the internationally significant Biosatellite space 
exploration program. As a result of this program and related activity, additional research, 
development and application of Bioscience techniques have been, and are now, being 
accomplished on salient Biomedical problems that have been identified. A brief description 
of pertinent tasks, in process or completed, is given in the accompanying paragraphs. 
1.1 	 BIOSATELLITE PROGRAM 
During the last several years, GE-RESD has been engaged in a number of programs with 
NASA and the medical community in the biological and medical fields. In the NASA Bio­
satellite Program, GE-RESD designed and built a number of space laboratories to study
the effects of relatively long-duration flights on a wide variety of plant and animal speci­
mens in controlled environments that could not be duplicated on earth. For details, see 
the supplement to Report No. 2 titled: "A Summary of Biosatellite Technologies". Flights 
were 	made in December 1966 and September 1967 to study the effects of weightlessness and 
radiation on several simple organisms. Thirteen experiments were carried on these flights, 
seven of the experiment' s organisms being exposed to gamma radiation from an on-board 
Strontium source. A third flight was made during June and July 1969 to study the effects of 
prolonged weightlessness on a primate, specifically its brain functions and performance, 
cardiovascular functions, metabolic functions and the bone density changes in various sites 
of the skeletal anatomy. 
The third Biosatellite Spacecraft demonstrated significant advances in the state-of-the-art 
of unmanned satellites. Since the Biosatellites carried no high-level intelligent life aboard, 
all data gathering and command functions were controlled either automatically or by remote 
control from the ground. 
1.2 	 MEDICAL DATA ACQUISITION UNIT lDAU) 
Under contract to the Metropolitan Life Insurance Company, GE-RESD has developed a 
portable unit for use by non-medical personnel for obtaining medical data on a prospective 
client as to their insurability. The data acquired includes: ECG, blood pressure, weight, 
overall height, waist to head length, and waist measurements. Evaluation of a prototype
unit is currently under way and ten additional units are to be fabricated. The circuit de­
signs, system concepts and experience developed on this system are directly applicable to 
the tasks proposed herein. 
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1.3 EXERCISE ELECTROCARDIOGRAM PROGRAM 
During the last several years, GE-RESD has been engaged with the Lankenau Hospital of 
Philadelphia, Pa., in conducting a long term Exercise Electrocardiogram (EECG) research 
program. The co-project directors and principal investigators of this program are 
Dr. J.W. Daly and Dr. G.J. Haupt. 
The long-term purpose of this project is to establish the electrocardiogram obtained during 
examination, as opposed to that obtained at rest or after exercise, as a fundamental clinical 
tool to: 
* 	 Detect early cardiac conditions in asymptomatic subjects. 
* 	 Determine safe activity levels for all types of cardiac patients. 
* Assist in training cardiac patients to accept, safely, increased activity levels. 
Among the benefits accuring to the field of vocational rehabilitation would be: 
* 	 Preventive rehabilitation by detection of incipient heart disease. 
* 	 Determination of employability. 
o 	 Correlation of safe work levels with job requirements. 
* 	 Repeated evaluation of work capability to provide guidelines for continuous job 
adjustment. 
The primary and secondary objectives of the current effort on this program are to establish 
an extensive EECG data base and to validate the data processing system respectively. 
The EECG data acquisition system is installed at Lankenan Hospital and the data processing 
system developed at GE-RESD is employed to obtain the data base. All data is processed at 
the GE-RESD data processing center. 
A bicycle ergometer is employed for exercise stress. The EECG signal is obtained via 
small disposable electrodes, continuously displayed on an oscilloscope for instantaneous 
observation by the attending physician, and permanently recorded on a strip chart recorder 
for permanent samples. Along with patient identification information, the EECG is recorded 
on magnetic tape on the hospital premises. 
At the data processing center, the EECG data is digitized as required for presentation to the 
digital computer for parameter extraction. A simplified block diagram of the EECG System 
is shown in Figure 1B-1. 
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Figure MI-1. Exercise Electrocardiogram System 
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The data base that is being established consists of EECG data fot each patient in three 
different formats. The raw data is stored on analog magnetic tapes recorded at the hospi­
tal and on digital magnptiq tapes generated from the analog tapes at the GE-RESD data 
processing center. The third format is microfilm tabulations and plots of EECG para­
meters obtainedfirom the parameter extraction computer program. 
The computer program measures 29 parameters (amplitudes of/widths of/intervals between 
waves) inthe EECG complex. Quality of the measured data is indicated by code words in 
the taluled output. 
Noise, which'i often a problem in cardiography, is removed by a specially designed low­
low pass digital filter which does not alter D.C. components and very nearly eliminates 
60 Hz components. Only the data between QRS complexes are so filtered, resulting in a 
rselectively smoothed" wave, partly filtered and partly raw data. This digital filter has 
proved-to be a very powerful tool for identifying the dominant wave (Ror S), estimating 
noise level, and identifying T and P waves. 
Special techniques are used to detect and eliminate spikes. 
GE-RESD has developed a data acquisition system which made it possible to acquire raw 
data with very low noise content over a nominal intelligence frequency range of 0.05 Hz to 
220 Hz. Based on the experience to date, the quality of the raw data will provide an 
excellent base for future EECG research. 
Some operational advantages of the dbta acquisition system are as follows: 
* Patient and procedural identification is 	by automatic digital encoding instead of by 
voice.
 
* 	 Procedural control is almost completely automatic rather than manual. 
1.4 RELATED BIOSCIENCE STUDIES 
In addition to the aforementioned programs, 	GE-RESD has had many years of applicable 
experience and background in the field of bioscience. Salient research and development 
programs In this area include the following: 
PROGRAM IDENTIFICATION 	 CONTRACTING AGENCY 
1. 	 Bone Demineralization Study USAF School of Aerospace Medicine 
Brooks AFB 
2. Studies of Pulmonary Circulation 	 NASA Headquarters (OART) 
3. 	 Mass Transport & Hemolysis in US Army M&RDC
 
Capillary Blood Oxygenator
 
Equipment
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PROGRAM IDENTIFICATION 	 CONTRACTING AGENCY
 
4. 	 Coronary Research Analytic Peter Bent Brigham Hospital, Boston, 
Support Mass. 
5. 	 Theoretical/Experimental Study Albert Einstein Medical Center
 
of the Myocardium Philadelphia

1 
6. 	 Physiological Systems Modeling NASA Manned Space - Houston, Tex. 
(Cardiovascular & Body Fluids) 
7. 	 Asceptic Maintenance by NASA Langley Research Center
 
Pressurization (AMP #3) - Hampton, Va.
 
Penetration of Bacteria Through
 
Small Holes
 
8. 	 Studies of Blood Flow in Artifi- NIH - Wash., D.C.
 
cial Blood Pumps
 
9.-	 Mass Transfer in Artificial U.S. Army
 
Oxygenators
 
1.5 RESEARCH AND DEVELOPMENT ACTIVITY 
The 	funding allocated to RESD and the GE Space Division at Valley Forge, Penna., for the 
CY-1970 Independent Research and Development (IR&D) Program was approximately seven 
million dollars. The proximity of, and the close working relationship between, the two GE 
Divisions allows continuous cross-correlation of results on individual programs/tasks 
regardless of organizational auspices for the specific tasks. The 	1970 IR&D tasks shown 
in Table JIB-1 are appropriate to the implementation of the PMS system and the R&D 
tasks defined herein. Results of the tabulated tasks will augment the activities proposed 
in this submittal. 
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TABLE ]IIB-1. IR&D PROGRAM TASKS APPLICABLE TO 
IMPLEMENTATION OF PROTOTYPE PMS AND R&D TASKS 
1o 	 HEALTH AND LIFE SCIENCE SYSTEMS 
- Bio-Isolation and Sterilization Techniques
 
- Non-invasive Medical Measurements
 
-
 Improved Phenol Analysis Techniques
 
- EECG Multi-Lead Data Acquisition
 
- Improved Portable Volume Control Respirator
 
- Computer-Assisted Diagnostcs
 
- Improved P0 2 Sensor
 
- Diagnostic and Predictive Bio-Medical Systems Development
 
- Electric Fields in Blood Clotting
 
- Multi-Measurement Body Plethysmograph
 
- Permselective Membranes
 
- Body Waste Treatment Systems
 
2. 	 INFORMATION AND DATA SYSTEMS 
- Data Search Systems 
- Two-Dimensional Optical Fourier Transforms by Varying Area Techniques 
- Advanced Discrete Data Techniques
 
- Universal Development and Demonstration Console
 
- Flexible Data Retrieval Subsystem
 
- Image Processing and Analysis
 
- Multi-Processing Techniques
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TABLE 1IBR-1. IR&D PROGRAM TASKS APPLICABLE TO 
IMPLEMENTATION OF PROTOTYPE PIS AND R&D TASKS (Continued) 
2. 	 CONTINUED 
- Information Management System Test Bed and Workshop Simulation 
- Data Bus Technology
 
- Distributed Processor/Interface Module Development
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